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Résumé 
Selon les lignes directrices de traitement  de l'asthme pendant la grossesse, les beta2-
agonistes inhalés à courte durée d’action (SABA) sont les médicaments de choix pour  tous 
les types d’asthme [intermittent, persistant, léger, modéré et sévère] comme médicaments 
de secours rapide et dans la gestion des exacerbations aiguës. D’autre part, les beta2-
agonistes inhalés à longue durée d’action (LABA) sont utilisés pour les patients atteints 
d'asthme persistant, modéré à sévère, qui ne sont pas entièrement contrôlés par des 
corticostéroïdes inhalés seuls. Malgré que plusieurs études aient examinées l’association 
entre les LABA, les SABA et les malformations congénitales chez les nouveau-nés, les 
risques réels restent controversés en raison de résultats contradictoires et des difficultés 
inhérentes à la réalisation d'études épidémiologiques chez les femmes enceintes. L'objectif 
de cette étude était d'évaluer l'association entre l'exposition maternelle aux SABA et LABA 
pendant le premier trimestre de grossesse et le risque de malformations congénitales chez 
les nouveau-nés de femmes asthmatiques. 
 
 Une cohorte de grossesses de femmes asthmatiques ayant accouchées entre le 1er 
janvier 1990 et le 31 décembre 2002 a été formée en croisant trois banques de données 
administratives de la province de Québec (Canada).  Les issues principales de cette étude 
étaient les malformations congénitales majeures de touts types. Comme issues secondaires, 
nous avons considéré des malformations congénitales spécifiques. L'exposition principale 
était la prise de SABA et/ou de LABA au cours du premier trimestre de grossesse. 
L'exposition secondaire étudiée était le nombre moyen de doses de SABA par semaine au 
cours du premier trimestre. 
 
L'association entre les malformations congénitales et la prise de SABA et de LABA 
a été évaluée en utilisant des modèles d’équations généralisées (GEE) en ajustant pour 
plusieurs variables confondantes reliées à la grossesse, l’asthme de la mère et la santé de la 
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mère et du fœtus. 
 
Dans la cohorte formée de 13 117 grossesses de femmes asthmatiques, nous avons 
identifié 1 242 enfants avec une malformation congénitale (9,5%), dont 762 avaient une 
malformation majeure (5,8%). Cinquante-cinq pour cent des femmes ont utilisé des SABA 
et 1,3% ont utilisé des LABA pendant le premier trimestre. Les rapports de cotes ajustées 
(IC à 95%) pour une malformation congénitale associée à l'utilisation des SABA et des 
LABA étaient de 1,0 (0,9-1,2) et 1,3 (0,9-2,1), respectivement. Les résultats correspondants 
étaient de 0,9 (0,8-1,1) et 1,3 (0,8-2,4) pour les malformations majeures. Concernant le 
nombre moyen de doses de SABA par semaine, les rapports de cotes ajustées (IC à 95%) 
pour une malformation congénitale était de 1.1 (1.0-1.3), 1.1 (0.9-1.3), et 0.9 (0.7-1.1) pour 
les doses >0-3, >3-10, and >10 respectivement. Les résultats correspondants étaient de 1.0 
(0.8-1.2), 0.8 (0.7-1.1), et 0.7 (0.5-1.0) pour les malformations majeures. D'autre part, des 
rapports de cotes (IC à 95%) statistiquement significatifs ont été observés pour les  
malformations cardiaques (2.4 (1.1-5.1)), les malformations d'organes génitaux (6.8 (2.6-
18.1)), et d'autres malformations congénitales (3.4 (1.4 à 8.5)), en association avec les 
LABA pris pendant le premier trimestre. 
 
 Notre étude procure des données rassurantes pour l’utilisation des SABA pendant la 
grossesse, ce qui est en accord avec les lignes directrices de traitement de l’asthme. 
Toutefois, d'autres études sont nécessaires avant de pouvoir se prononcer sur l’innocuité 
des LABA pendant la grossesse.  
 
 
Mots-clés : asthme, grossesse, malformations congénitales, beta2-agonistes, étude de 
cohorte. 
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Abstract 
According to asthma management guidelines during pregnancy, short-acting β2-
agonists (SABA) are the drug of choice in all types of asthma [intermittent or persistent, 
mild, moderate and severe] as a quick reliever medication and in the management of acute 
exacerbations or emergency hospitalizations. On the other hand, long-acting β2-agonists 
(LABA) are used for patients with moderate and severe persistent asthma not fully 
controlled with inhaled corticosteroids alone. While many studies examined their 
associations with congenital malformations in newborns, the actual risks remain 
controversial due to the discordance between different risk reports and the difficulties in 
performing epidemiological studies on pregnant women. The objective of this study is to 
investigate the association between maternal exposure to SABA and LABA during the first 
trimester of pregnancy and the risk of congenital malformations in the newborns among 
asthmatic women. 
 
Through the linkage of three administrative databases from Québec, a cohort of 
pregnancies from asthmatic women insured by the RAMQ drug insurance plan was formed 
between January 1, 1990 and December 31, 2002. The primary outcomes were major and 
any congenital malformations and the secondary outcomes were specific malformations. 
The primary exposure was the separate exposure to SABA and LABA during the first 
trimester, while the secondary exposure was the average number of doses of SABA per 
week taken during the first trimester. The association between congenital malformations 
and SABA and LABA exposure was assessed using generalized estimating equation 
models while adjusting for sociodemographic, asthma, maternal and fetal variables.  
 
We identified 1242 infants with a congenital malformation (9.5%), 762 of which 
had a major malformation (5.8%) within the cohort formed of 13117 pregnancies. Fifty-five 
percent of the women used SABA during the first trimester, and 1.3% used LABA. The 
adjusted odds ratio (95% CI) for any malformation associated with the use of SABA and 
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LABA were 1.0 (0.9-1.2) and 1.3 (0.9-2.1), respectively. The corresponding figures were 
0.9 (0.8-1.1) and 1.3 (0.8-2.4) for major malformations. Regarding the average number of 
doses of SABA per week, the adjusted odds ratio (95% CI) for any malformation were 1.1 
(1.0-1.3), 1.1 (0.9-1.3), and 0.9 (0.7-1.1) for doses >0-3, >3-10, and >10 respectively. The 
corresponding figures were 1.0 (0.8-1.2), 0.8 (0.7-1.1), and 0.7 (0.5-1.0) for major 
malformations. On the other hand, significant increased risks, odds ratio (95% CI), of 
cardiac malformations 2.4 (1.1-5.1), genital organ malformations 6.8 (2.6-18.1), and other 
congenital malformations 3.4 (1.4-8.5) were observed with LABA use in the 1st trimester. 
 
Our study adds evidence, in concordance with asthma management guidelines, to 
the safety of SABA during pregnancy. However, more research is needed before we can 
decide on the safety of LABA during pregnancy. 
 
 
Keywords: asthma, pregnancy, congenital malformations, beta2-agonists, cohort study. 
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Preface 
 
This Msc thesis consists of six chapters including an introduction, a review of the 
literature, the objectives of the study, the methods, the manuscript of an article submitted 
for publication, and a discussion section. These chapters are followed by a bibliography 
section. 
  
The introduction chapter provides the rationale and general objectives of the study 
we performed. The review of the literature covers different aspects on the subject of our 
study and provides an overview on the results relevant to our project with focus on asthma 
during pregnancy. The objectives chapter presents the general, primary, and secondary 
objectives of our research project. The methodology chapter comprehends the information 
presented under the “Methodology” section in the manuscript more comprehensively. The 
manuscript chapter contains an article reporting the results of our study on the use of SABA 
and LABA during pregnancy and the risk of congenital malformations. This manuscript 
was submitted to Birth defects research: part A. The discussion chapter presents the 
strengths and limitations of our project, the contribution of our results to the literature in the 
field of asthma during pregnancy, the clinical implications of our results, further research 
recommendations and it ends with an overall conclusion. The bibliography section contains 
all articles, books, and reports cited in this thesis, however the manuscript includes its own 
bibliography. 
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Introduction 
Asthma has been recognized as one of the most common chronic pulmonary 
diseases and a serious medical complication in pregnancy.[1-3] The disease affects about 
3.7% to 8.4% of pregnant women and shows an increasing prevalence over time.[1;2] 
Pregnancy outcomes of asthmatic women compared to non-asthmatic women were 
examined in many studies, and have shown increased risks of both maternal and fetal 
outcomes among asthmatic mothers.[1;4] From the maternal outcomes that were reported to 
increase among asthmatic women versus non-asthmatic women were preeclampsia, 
antepartum hemorrhage, hypertensive disorders, cesarean delivery, placenta previa, and 
postpartum bleeding. While the adverse fetal outcomes include small for gestational age 
infants, low birth weight, preterm labor, transient tachypnea of the newborn, neonatal 
hypoxia, and neonatal hyperbilirubinemia. [4;5] 
More specifically, uncontrolled and severe asthma during pregnancy has been 
shown to have potential harmful effects.[1;4;6;7] Most studies suggest that more severe 
asthma during pregnancy is associated with increased fetal and maternal risks [1;4], while 
better-controlled asthma is associated with decreased risks.[5] Therefore benefit-risk 
comparisons often favor the use of asthma medications during pregnancy to maintain 
asthma under control.[3] 
From the adverse effects of uncontrolled maternal asthma is the association with 
intra uterine growth restriction (IUGR), prematurity, and congenital malformations that 
may lead to compromised fetal growth.[1;8-11] Two main potential mechanisms have been 
hypothesized to explain these observations :(1) fetal hypoxia due to poor maternal asthma 
control and (2) asthma medications used to treat asthma.[12] 
Treatment and control of asthma could be achieved by using several medications. 
Even if  some of them are accepted and widely used during pregnancy,  none has been 
classified as completely safe for use during pregnancy or located in category “A” in the 
FDA classification of medications used during pregnancy.[3;13] Asthma medications can 
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be categorized into two classes, the first class includes the quick relief medications, i.e. the 
short-acting beta2-agonists (SABA). The second class includes long-term controller 
medications, i.e. inhaled corticosteroids, long-acting beta2-agonists (LABA), mast cell 
stabilizers, methylxanthines, and leukotriene receptors antagonists. 
SABA have been widely used for years to relief asthma symptoms during 
pregnancy, which is not the case for LABA. More data on the safety of SABA than LABA 
during pregnancy are available in the literature due to their precedence in the 
markets.[3;14] According to the US National Asthma Education and Prevention Program 
guidelines for managing asthma during pregnancy, SABA are the drug of choice in all 
types of asthma [intermittent or persistent, mild, moderate and severe] as a quick reliever 
medication and in the management of acute exacerbations or emergency hospitalizations. 
On the other hand,  LABA are used for patients with moderate and severe persistent asthma 
not fully controlled with inhaled corticosteroids alone.[3]  
Congenital malformations are present in approximately 3% of live births,[15] and 
they are considered the leading cause of infants mortality in the USA and Canada.[16;17] 
Major congenital malformations are considered as one of the primary outcomes when 
studying the safety of medications used during pregnancy. Congenital malformations put 
children at risk of developmental delay and morbidities in both childhood and adulthood. 
Children with malformations are more susceptible to health problems and lifelong 
disabilities, besides having a shorter life expectancy than their healthy peers.[18-20] Beside 
its direct effect on the population health, congenital malformations are considered a heavy 
economic burden for both the family and society. [18;19] 
Moreover, we can’t neglect the psychological impact of birth defects on parents and 
families. The presence of negative pregnancy experiences and infants with disabilities are 
related with a higher risk of mental health problems for mothers, especially 
depression.[18;21] Also from the psychological disorders that affect the parents are 
excessive parenting stress, distress and hopelessness, resulting in lower quality of life.[22-
25] 
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The association between the use of SABA and LABA during pregnancy and the risk 
of congenital malformations was the object of 15 different studies [14;26-39]: 8 studies 
investigated the risk of congenital malformations associated with the use of SABA and 
LABA separately.[14;26;27;33-36] From these 8 studies, 4 used a control group of 
asthmatic women,[14;35;36;39] with only one of them reporting a significant increased risk 
of congenital malformations with Fenoterol (SABA) use (pOR=1.6, 95% CI=1.3-2.0).[36] 
Nevertheless, it is not possible to conclude on the safety of these medications during 
pregnancy since there were many important methodological limitations in most of these 
studies. The interpretation of the study results is often difficult due to low statistical power, 
timing of the exposure during pregnancy, and incomplete adjustment for asthma 
severity/control and other important confounders.[14;35;36;39] While investigating SABA 
and LABA and their association with congenital malformations, important potential 
confounders should be taken into consideration, including socio-demographic variables, 
maternal and fetal conditions, and asthma related variables. Due to the difficulty of drawing 
valuable and explicit conclusions about the safety of SABA and LABA in pregnancy, we 
performed a study with primary objectives of evaluating the association between maternal 
exposure to SABA and LABA during the first trimester of pregnancy and major and any 
congenital malformations. Moreover, the secondary objective of our study was to examine 
the same associations with specific congenital malformations. 
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Review of the literature 
 
2.1 Asthma and its prevalence 
Asthma is a complex disorder characterized by variable and recurring symptoms, 
airflow obstruction, bronchial hyper-responsiveness, and an underlying inflammation.[40] 
According to the Global Initiative for Asthma (GINA) guidelines, asthma is defined as “a 
chronic inflammatory disorder of the airways in which many cells and cellular elements 
play a role. The chronic inflammation is associated with airway hyper-responsiveness that 
leads to recurrent episodes of wheezing, breathlessness and coughing particularly at night 
or in the early morning. These episodes are usually associated with wide spread, but 
variable, airflow obstruction within the lung that is often reversible either spontaneously or 
with treatment”.[41]  
 
Asthma is considered one of the most common chronic diseases affecting an 
estimated 300 million people worldwide.[40;41] Moreover, considerably higher estimates 
can be obtained with less conservative criteria for the diagnosis of clinical asthma.[40] The 
prevalence of asthma increased very markedly over the last 50 years of the past century, 
especially in westernized societies, where it now poses a considerable burden on 
individuals and economic disease burden on healthcare systems and society.[42;43] The 
prevalence of asthma in Canada and the United States is amongst the highest in the world 
for both children and adults, reaching about 10% to 11.2%.[42;44] 
 
2.2 Asthma severity and control 
While being complementary notions in the management of asthma, asthma severity 
and control may overlap in their ways of assessment and each has its distinguished clinical 
importance.[40;41]  
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2.5.1 Asthma severity 
According to the US National Asthma Education and Prevention Program 
guidelines for the diagnosis and management of asthma, asthma severity is defined 
as the intrinsic intensity of the disease process.[40] Severity is most easily and 
directly measured in a patient who is not receiving long-term control therapy.[45] 
Severity can also be measured, once asthma control is achieved, by the step of care 
(i.e., the amount of medication) required to maintain control.[40] According to US 
National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma and in common daily practice, asthma severity is 
measured taking into account many factors which include the level of asthma 
symptoms, night-time symptoms, use of SABA for quick relief, pulmonary function 
and airway limitation, rate of exacerbations, and limitations to normal activities.[40] 
Using these factors, asthma severity level according to US National Asthma 
Education and Prevention Program guidelines was classified into four categories; 
intermittent, mild persistent, moderate persistent, and severe persistent (see Table 1 
and 2).[40] The stepwise approach for managing asthma in adults is then used to 
manage asthma in each patient according to his severity level (see Figure 1). On the 
other hand, according to the recent Global Initiative for Asthma (GINA) guidelines, 
asthma severity is classified according to the intensity of the treatment required to 
achieve efficient asthma control.[41]  
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Table 1. Classification of asthma severity measured before treatment is started 
according to US National Asthma Education and Prevention Program guidelines 
 Clinical features before treatment# 
 Symptoms¶ 
Night-time 
symptoms 
Lung 
function 
Severe 
persistent 
Continual symptoms 
Limited physical activity 
Frequent exacerbations 
Frequent 
FEV1 or PEF 
≤60% pred 
PEF 
variability 
>30% 
 Moderate 
persistent 
Daily symptoms 
Daily use of inhaled SABA 
Exacerbations affect activity 
Exacerbations more than twice per 
week; may last days 
More than 
once per week 
FEV1 or PEF 
>60 and 
≤80% pred 
PEF 
variability 
>30% 
Mild 
persistent 
Symptoms more than twice per week but 
no more than once per day 
Exacerbations may affect activity 
More than 
twice per 
month 
FEV1 or PEF 
≥80% pred 
PEF 
variability 
20–30% 
Intermittent 
Symptoms no more than twice per week 
Asymptomatic and normal PEF between 
exacerbations 
Exacerbations are brief (from a few 
hours to a few days); intensity may vary 
No more than 
twice per 
month 
FEV1 or PEF 
≥80% pred 
PEF 
variability 
<20% 
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Asthma severity was classified by clinical characteristics before treatment. FEV1: forced expiratory volume in 
one second; PEF: peak expiratory flow; % pred: % predicted; SABA: short-acting β2-agonist. #: the presence of 
one of the features of severity is enough to place the patient in that category. An individual should be assigned 
to the most severe grade in which any feature occurs. An individual’s classification may change over time. ¶: 
Patients at any level can have mild, moderate or severe exacerbations. Some patients with intermittent asthma 
experience severe and life-threatening exacerbations separated by long periods of normal lung function and no 
symptoms. 
From US National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma, Expert Panel Report 3, 2007 
 
 
Table 2. Classifying severity in patients after asthma becomes well controlled, by lowest 
level of treatment required to maintain control. 
Classification of Asthma Severity 
Intermittent Persistent 
Step 1 
Mild Moderate Severe 
Step 2 Step 3 or 4 Step 5 or 6 
From US National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma, Expert Panel Report 3, 2007 
 
3.5.1 Asthma control 
According to the US National Asthma Education and Prevention Program 
guidelines for the diagnosis and management of asthma,[40] asthma control is 
defined as the degree to which the manifestations of asthma are minimized by 
therapeutic intervention and the goals of therapy are met.[40] The assessment of 
asthma control is done through measuring the components of control which include 
level of asthma symptoms, night-time awakenings, interference with normal 
activities, SABA use for quick relief of symptoms, pulmonary function (FEV1 or 
peak flow), exacerbations, the progressive loss of lung function, and the treatment 
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related side-effects[40] According to the US National Asthma Education and 
Prevention Program guidelines for the diagnosis and management of asthma, asthma 
control is classified into three classes; well controlled, not well controlled and very 
poorly controlled (see Table 3).[40] The Global Initiative for Asthma (GINA) 
guidelines uses similar aspects for measuring asthma control, and classifies it into 
controlled, partly controlled, and uncontrolled.[41] 
 
Table 3. Classification of asthma control in adults according to US National Asthma 
Education and Prevention Program guidelines 
COMPONENTS 
OF CONTROL 
CLASSIFICATION OF ASTHMA CONTROL 
 
 
WELL 
CONTROLLED 
NOT WELL 
CONTROLLED 
VERY POORLY 
CONTROLLED 
Impairment 
Symptoms ≤ 2 days/week > 2 days/week Throughout the day 
Night-time 
awakenings 
≤ 2 times/month 1–3 times/week ≥ 4 times/week 
Interference with 
normal activity 
None Some limitation Extremely limited 
Short-acting beta-
2- agonist 
use for symptom
control 
(not prevention of
exercise- 
induced 
bronchospasm) 
≤ 2 days/week > 2 days/week Several times/day 
  
 
11
FEV1 or peak flow  
> 80% predicted or
personal best 
60%–80% predicted or 
personal best 
< 60% predicted or 
personal best 
Validated questionnaires 
 ATAQ 0 1–2 3–4 
 ACQ ≤ 0.75 ≥ 1.5 NA 
 ACT ≥ 20 16–19 ≤ 15 
Risk 
Exacerbations 
requiring oral
systemic 
corticosteroids 
0–1/year 2–3/year  > 3/year 
 Consider severity and interval since last exacerbation. 
Progressive loss of
lung function 
Evaluation requires long-term follow-up care. 
Treatment-related 
adverse effects 
Medication side effects can vary in intensity from none to very
troublesome and worrisome. The level of intensity does not correlate
to specific levels of control but should be considered in the overall
assessment of risk.  
ATAQ = Asthma Therapy Assessment Questionnaire, ACQ = Asthma Control Questionnaire, ACT = Asthma 
Control Test, FEV1 = forced expiratory volume in 1 second. 
From US National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma, Expert Panel Report 3, 2007 
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Figure 1. Stepwise approach for managing asthma in adults according to US 
National Asthma Education and Prevention Program guidelines 
 
Source: US National Asthma Education and Prevention Program guidelines for the 
diagnosis and management of asthma, Expert Panel Report 3, 2007 
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2.3 Asthma management and treatment 
Asthma treatment goal is to prevent and control asthma symptoms, reduce the 
frequency and severity of asthma exacerbations, and reverse airflow obstruction.[40] 
Recommendations in the treatment choices reflect the scientific fact that asthma is a 
chronic disorder with episodes of airflow limitation, cough, and mucus production.[45] 
Asthma medications are thus categorized into two classes: quick-relief medications which 
are  taken to achieve prompt reversal of acute pulmonary obstruction and relief of the 
accompanying broncho-constriction (these medications are also known as acute rescue or 
reliever medications) and long-term-control medications which are taken daily on a long-
term basis to achieve and maintain control of persistent asthma (these medications are also 
known as long-term preventive, maintenance, or controller medications). Patients with 
persistent asthma are in need of both classes of medication. [3;40;41]  
 
2.3.1 Controller medications 
Controller medications should be taken daily on a long-term basis in order to keep 
asthma under control. The most effective are those that attenuate the underlying 
inflammation characteristic of asthma.[40;41]  
• Corticosteroids: Most potent and effective anti-inflammatory medication 
currently available. Inhaled corticosteroids (ICS) have fewer side effects than 
oral or systemic corticosteroids, and are used in the long-term control of 
asthma. [40;41] From the commonly used ICSs: Beclomethasone dipropionate, 
Budesonide, Ciclesonide, Flunisolide, Fluticasone propionate, Mometasone 
furoate, Triamcinolone acetonide.[40;41] ICSs are the most effective long-term 
controller medications in all levels of persistent asthma, and they have 
superiority over any other single long-term controller medication.[40] 
Systemic corticosteroids are often used to gain prompt control of the 
disease.[40;41] Long-term oral corticosteroids therapy (tablets or syrup) are 
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used only if needed in cases of severe persistent uncontrolled asthma (see 
Figure 1), with favouring their discontinuation as soon as asthma control is 
regained.[40;41] 
• Cromolyn sodium and Nedocromil: Mild to moderate anti-inflammatory 
medications. They are recommended as an alternative, but not preferred, 
medication for patients at step 2 in asthma management (mild persistent 
asthma) (see Figure 1). They also can be used as preventive treatment prior to 
exercise or unavoidable exposure to known allergens.[40] 
• Leukotriene modifiers: Zafirlukast or Montelukast may be considered an 
alternative therapy to low doses of inhaled corticosteroids or Cromolyn or 
Nedocromil for patients with mild persistent asthma. Also as add-on therapy in 
patients not sufficiently controlled by ICSs (see Figure 1). [40] 
• Methylxanthines: Sustained-release Theophylline is a mild-to-moderate 
bronchodilator used principally as adjuvant to inhaled corticosteroids for 
prevention of nocturnal asthma symptoms.[40]  
• Long-acting beta2-agonists (LABA): Long-acting bronchodilators 
(Salmeterol and Formoterol) are used concomitantly with ICS for long-term 
control of symptoms, especially nocturnal symptoms. LABA have duration of 
bronchodilator of at least 12 hours after a single dose. These medications 
should not be taken alone in asthma as they don’t have enough effect on the 
airway inflammation of asthma. [40] LABA are recommended in combination 
with ICSs for long-term control in moderate and severe persistent asthma (step 
3 to 6 in the stepwise approach for managing asthma, see Figure 1).[40] The 
combination of LABA and ICS is the recommended and preferred choice when 
a medium dose of ICS fails to achieve the efficient control of asthma.[41] 
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2.3.2 Relievers  
Those are quick-relief medications which are used to treat acute symptoms and 
exacerbations. [40;41] 
• Short-acting beta2-agonists (SABA): Including Salbutamol, Terbutaline, 
Fenoterol, Levalbuterol, Metaproterenol, and Pirbuterol, SABAs are 
considered therapy of choice for relief of acute asthma symptoms, acute 
exacerbations and pre-treatment of exercise-induced broncho-constriction (see 
Figure 1). [40;41]  
• Anticholinergics: Ipratropium bromide provides additive benefit to inhaled 
beta2-agonists in severe exacerbations. May act as alternative bronchodilator 
for patients intolerant to inhaled beta2-agonists. [40;41]  
• Systemic corticosteroids: Short courses of oral corticosteroids or parenteral 
corticosteroid solutions are used for moderate to severe exacerbations to speed 
recovery and prevent recurrence of exacerbations.[40] They include 
Prednisone, Prednisolone, and Methylprednisolone.[40] 
 
2.4 Asthma during pregnancy 
Asthma is considered as one of the most frequent chronic diseases that affects 
pregnant women.[3;9] Asthma has a prevalence of 3.7 to 8.4% among pregnant 
women.[2;9;29] Moreover, a study showed a presence of an overall increasing prevalence 
of asthma during pregnancy over time.[46] 
 
2.4.1 Impact of pregnancy on asthma 
The rule of thirds applies to asthmatic pregnant women, where approximately one 
third of the patients suffer from worsening of their asthma symptoms, one third experience 
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improvement, while one third of the pregnant women have their asthma symptoms 
remaining unchanged.[47;48] In a meta-analysis of 14 studies, the distribution of changes 
in asthma symptoms during pregnancy was in agreement with the rule of thirds, however in 
some studies, the distribution may be still population-dependant.[49] 
It has also been suggested by many studies that the more severe the asthma, the 
more likely it is to worsen during pregnancy.[4;50;51] The fewest symptoms occur after 
week 37, nearly 75% of women return to their pre-pregnancy status within 3 months after 
delivery, the change in course of asthma tends to be consistent during successive 
pregnancies and exacerbations during delivery are rare.[3;4;51;52] The unsolved issue in 
this subject is determining the mechanism behind these changes. Asthma is an extremely 
variable disease, and a number of physiologic changes occur during pregnancy which could 
worsen or improve asthma.[4;51] The most important recommendation that should be 
followed is that since the course of asthma can change during pregnancy, therefore 
pregnant women need to be followed up more closely, and their therapy should be adjusted 
to achieve control of symptoms.[3;4;52] 
 
2.4.2 Impact of asthma on pregnancy 
Pregnancy outcomes of asthmatic women compared to non-asthmatic women were 
examined in many studies, and have shown increased risks of both adverse maternal and 
fetal outcomes among asthmatic mothers.[53] From the maternal outcomes that were 
reported to increase among asthmatic women versus non-asthmatic women were 
preeclampsia, antepartum hemorrhage, hypertensive disorders, cesarean delivery, placenta 
previa, and postpartum bleeding. While the adverse fetal outcomes include: small for 
gestational age infants, low birth weight, preterm delivery, congenital malformations, 
transient tachypnea of the newborn, neonatal hypoxia, and neonatal hyperbilirubinemia.[53-
55] 
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The critical effect of asthma during pregnancy on the fetal development is 
demonstrated through the possibility of inducing hypoxia combined with acute or 
compensated respiratory acidosis, besides an acute respiratory alkalosis that decreases the 
placental blood flow, increases systemic and pulmonary vascular resistance, and decreases 
cardiac output.[56;57] In cases of fetal lack of oxygen, the oxygen extraction rate by fetal 
tissues increases and could lead to long term effects of hypoxia as intrauterine growth 
retardation, preterm birth, neonatal hypoxia or perinatal morbidity and mortality.[57-60] 
 
Severe or uncontrolled asthma is associated with adverse fetal outcomes including 
perinatal mortality, IUGR, preterm birth, low birth weight, and congenital 
malformations.[3;11;47;55;61] On the other hand, it has been shown that women with well 
controlled asthma and proper treatment have little or no increased risk of adverse fetal 
outcomes.[3;47;62;63] 
 
An acute exacerbation of asthma is commonly referred to as an asthma attack. Some 
patients could have stable asthma for months and then suddenly suffer from an episode of 
acute asthma.[40] The symptoms of an attack are dyspnoea, wheezing, cough, and chest 
tightness. The cough in an acute attack may sometimes produce clear sputum. The onset 
may be sudden, with a feeling of constriction in the chest, breathing becomes difficult, and 
wheezing occurs.[40;41] 
 
Due to its potential risks on the fetal development and the severe problems they 
could contribute to,[11;64-66] exacerbations in pregnancy should be managed as soon as 
their signs and symptoms are recognized.[3] Exacerbations are potentially dangerous to the 
fetus as it can provoke maternal hypoxia combined with respiratory alkalosis, which could 
decrease the placental blood flow.[11;67] Hypoxia resulting from exacerbations could 
cause abnormal development of the fetus,[68] and they have been found to be associated 
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with an increased risk of cleft lip and palate in mice.[69] Exacerbations are common during 
pregnancy, reaching about 30% among pregnant women with severe asthma.[70] Asthma 
exacerbations have been found to be associated with adverse perinatal outcomes in some 
studies e.g. low birth weight and congenital malformations.[11;71]  
 
2.4.3 Pharmacologic treatment of asthma during pregnancy 
According to the US National Asthma Education and Prevention Program 
guidelines for managing asthma during pregnancy, the pharmacologic management of 
asthma during pregnancy postulates that the safer for the pregnant patients is to be treated 
with asthma medications than to have asthma symptoms or exacerbations and reduced lung 
function which could affect the fetal oxygen supply.[3;45] The type and amount of 
medications required to manage each patient are determined according to the severity of the 
patient’s asthma. 
 
According to the US National Asthma Education and Prevention Program 
guidelines for managing asthma during pregnancy,[3] asthma control is defined as 
minimizing the chronic asthma symptoms during the day or night, minimizing asthma 
exacerbations, achieving no limitations on daily activities, maintenance of normal 
pulmonary function, minimal use of SABA, and minimizing the medications side 
effects.[3] While they both aim to achieve asthma control, the difference in the treatment 
goal between asthmatic pregnant women and other non pregnant patients is that the optimal 
therapy should maintain control of asthma not only for the health and the quality of life of 
the patient, but also for the normal fetal development throughout gestation.[3;40] 
According to US National Asthma Education and Prevention Program guidelines, there is 
not much differences between the treatment of asthma in pregnant and non pregnant 
patients, apart from the fact that the stepwise approach for the pregnant patients is classified 
into 4 steps, while it is classified into 6 steps for non pregnant patients (see Figure 1 and 
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Table 4). The  main differences between the two stepwise approaches are; 1) the use of 
Zileuton in steps 3 and 4 (moderate persistent asthma) among non pregnant patients (see 
Figure 1) , 2) use of Omalizumab for patients who have allergies in steps 5 and 6 (severe 
persistent asthma) among non pregnant patients (see Figure 1), and 3) the recommendations 
for making repeated attempts to reduce systemic corticosteroid levels in pregnant patients 
suffering from severe persistent asthma (step 4) (see Table 4).   
 
Asthma medications used during pregnancy are categorized into 2 classes, the first 
class is the quick relief medications that are taken as needed in order to treat asthma 
symptoms and exacerbations.[3;40] This class includes SABA, anticholinergics and short-
courses of systemic corticosteroids. The second class includes long-term controllers which 
are ICS, long-term systemic corticosteroids, LABA, cromones, methylxanthines, and 
leukotriene modifiers. 
The principal action of beta2-agonists is to relax airway smooth muscle by 
stimulating beta2-receptors, thus increasing cyclic AMP and producing functional 
antagonism to broncho-constriction. Both SABA and LABA are believed to have similar 
mechanism of actions when taken by inhalation; the only difference with LABA is that 
their broncho-dilating effect could last for 12 hours after a single inhalation.[3;40;72] 
Therefore, the positioning of SABA and LABA in the stepwise approach of managing 
asthma during pregnancy is crucial in understanding their use, effect and their 
importance.[3] 
Another great concern that faces the endeavors to achieve optimal asthma control is 
the non-adherence of asthmatic pregnant women to their asthma medications due to their 
fears of a potential harm to their fetus.[47] In an online survey asking pregnant women 
aged 18 to 44 years old about their attitudes toward medication use, 39 % of the women 
reported having discontinued or reduced it, and one third of them did so without their 
physician consultation.[73] Another analysis showed that among women using asthma 
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medications before pregnancy, SABA claims were reduced by 52% during pregnancy and 
ICS by 36%.[74]  Moreover, it is believed that the actual proportion of pregnant women 
that are non-adherent to asthma medications are even higher than these reported 
percentages.[47] 
According to the US National Asthma Education and Prevention Program 
guidelines for managing asthma during pregnancy,[3] asthma clinical severity is classified 
into the following classes; 1) mild intermittent, 2) mild persistent, 3) moderate persistent, 
and 4) severe persistent (same classification as the one presented for adult asthmatic 
presented in table 1). However, the stepwise approach for managing asthma during 
pregnancy classifies asthma in 4 steps only and not into 6 as the stepwise approach for 
managing asthma in adults. (see Figure 1 and table 4). In order to achieve the desired 
clinical control of asthma symptoms, the stepwise approach is used to manage asthma 
during pregnancy (see table 4).[3] In cases of mild intermittent asthma, a SABA is used on 
an as-needed basis to treat asthma symptoms, and it is usually enough for this type of 
asthma. The recommendations imply that if the patient’s symptoms are relieved and the 
pulmonary functions are normalized, SABA can be continued on an as-needed basis but not 
more than 2 times per week.[3] Moreover, for patients experiencing exercise-induced 
bronchospasm, SABA should be used shortly before exercise (see Table 4).[3;45] In cases 
of mild intermittent asthma and exercise induced bronchospasm, Salbutamol (Albuterol) is 
the preferred SABA due to the safety profile for both pregnant and non-pregnant women 
(see Table 4). Also the greatest amount of efficacy and safety data during pregnancy could 
be found with Salbutamol.[3] 
 
Regarding persistent asthma, it is classified into mild, moderate and severe (see 
Table 4). SABA are used in all those types of persistent asthma as quick relief medications, 
with salbutamol as the drug preferred and the intensity of the treatment depending on the 
severity of asthma exacerbations. However, the use of SABA more than 2 times a week in 
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intermittent asthma (on a daily basis or increasing use in persistent asthma) may indicate 
the need to initiate or increase controller therapy (see Table 4).[3] 
 
Table 4. Stepwise Approach for Managing Asthma during pregnancy and lactation: 
Treatment 
Classify Severity: Clinical Features 
Before Treatment or Adequate 
Control 
Medications Required To Maintain Long-Term 
Control 
Symptoms/Day 
--------------------- 
Symptoms/Night 
PEF or FEV1 
---------------- 
PEF Variability
Daily Medications 
 
 
 
Step 4 Severe Persistent 
Continuous 
-------------- 
Frequent 
<60% 
------------- 
>30% 
Preferred treatment: 
- High-dose inhaled corticosteroid 
AND 
- Long-acting inhaled beta2-agonist 
AND, if needed, 
- Corticosteroid tablets or syrup long term (2 
mg/kg per day, generally not to exceed 60 
mg per day) (Make repeat attempts to reduce 
systemic corticosteroid and maintain control 
with high-dose inhaled corticosteroid.*) 
Alternative treatment: 
- High-dose inhaled corticosteroid* 
AND 
- Sustained release theophylline to serum 
concentration of 5–12 micrograms/mL 
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Step 3 Moderate Persistent 
Daily 
------------------ 
>1 night/week 
>60%-<80% 
------------ 
>30% 
Preferred treatment:  
EITHER 
- Low-dose inhaled corticosteroid* and long-
acting inhaled beta2-agonist 
OR 
- Medium-dose inhaled corticosteroid* 
If needed (particularly in patients with 
recurring severe exacerbations): 
- Medium-dose inhaled corticosteroid* and 
long-acting inhaled beta2-agonist. 
Alternative treatment:  
- Low-dose inhaled corticosteroid* and 
either theophylline or leukotriene receptor 
antagonist** 
If needed: 
- Medium-dose inhaled corticosteroid* and 
either theophylline or leukotriene receptor 
antagonist** 
Step 2 Mild Persistent 
>2 days/week but 
<daily 
----------------- 
>2 nights/month 
>80% 
------------- 
20 to 30% 
Preferred treatment:  
- Low-dose inhaled corticosteroid* 
Alternative treatment (listed alphabetically): 
cromolyn, leukotriene receptor antagonist** 
OR sustained-release theophylline to serum 
concentration of 5–12 micrograms/mL. 
Step 1 Mild Intermittent 
<2 days/week 
----------------- 
<2 nights/month 
>80% 
----------- 
<20% 
No daily medication needed.  
Severe exacerbations may occur, separated by 
long periods of normal lung function and no 
symptoms. A course of systemic 
corticosteroid is recommended. 
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Quick Relief All Patients 
Short-acting bronchodilator: 2-4 puffs short-acting inhaled beta2-agonist*** as needed 
for symptoms  
Intensity of treatment will depend on severity of exacerbation; up to 3 treatments at 20-
minute intervals or a single nebulizer treatment as needed. Course of systemic 
corticosteroid may be needed.  
Use of short-acting inhaled beta2-agonist*** >2 times a week in intermittent asthma 
(daily, or increasing use in persistent asthma) may indicate the need to initiate 
(increase) long-term-control therapy. 
 
Step Down  
Review treatment every 1 to 6 months; a gradual stepwise reduction in treatment may be 
possible.  
Step up  
If control is not maintained, consider step up. First, review patient medication technique, 
adherence, and environmental control.  
Goals of Therapy: Asthma Control 
Minimal or no chronic symptoms day or night  
Minimal or no exacerbations  
No limitations on activities; no school/work missed  
Maintain (near) normal pulmonary function  
Minimal use of short-acting inhaled beta2- agonist***  
Minimal or no adverse effects from medications 
* There are more data on using budesonide during pregnancy than on using other inhaled corticosteroids. 
** There are minimal data on using leukotriene receptor antagonists in humans during pregnancy, although 
there are reassuring animal data submitted to FDA. 
*** There are more data on using albuterol during pregnancy than on using other short-acting inhaled beta2-
agonists. 
Source: National Asthma Education and Prevention Program. Managing asthma during 
pregnancy: recommendations for pharmacologic treatment; National Heart, Lung, and 
Blood Institute; 2005  
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While SABA are indicated in all asthma types as a reliever medication, and ICS 
being the cornerstone therapy in the management of persistent asthma during pregnancy, 
LABA (Salmeterol and Formoterol) are used in cases of moderate and severe persistent 
asthma (see table 4), in combination with low or medium dose inhaled corticosteroids. Due 
to the limited number of studies on LABA during pregnancy, guidelines and practitioners 
commonly expect them to have a safety profile similar to Salbutamol.[3;41] Moreover, the 
choice between Salmeterol and Formoterol is not supported with enough data, but 
Salmeterol is preferred as it has been available in the markets for a longer period of time 
than Formoterol.[3;41;72] 
 
Beside their potential role in the pharmacologic management of asthma symptoms, 
SABA have a crucial role in the management of acute exacerbations during pregnancy, 
both home managed and hospital or clinic managed.[40;75] For the home management, the 
pregnant women are recommended to use inhaled Salbutamol. In the hospital and clinic 
management, Salbutamol also is the recommended drug during pregnancy used through a 
nebulizer.[3] 
 
The U.S. Food and Drug Administration (FDA) introduced in 1979 the Drugs in 
Pregnancy category system in which one of five letters (A, B, C, D, X) and their 
corresponding definition texts are used to summarize pregnancy information and safety of a 
certain drug. Both SABA and LABA are categorized in risk category C, [13;47] which 
stipulate that risk cannot be ruled out, animal reproduction studies have shown an adverse 
effect on the fetus and there are no adequate and well-controlled studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despite potential 
risks.[13] However, criticism have been raised against the FDA rating system as these 
categories are based on experimental animal and human gestational data submitted to the 
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FDA and not necessarily published, also a consideration was raised on whether the risk-
benefit comparisons would favor the use of certain drugs during pregnancy.[3;47]  
 
No asthma medication is placed in category A, [3;13] and that could be due to the 
requirement of well-controlled studies in pregnant women, which is ethically very difficult. 
Moreover, the FDA categorization does not take into account all published human or 
animal gestational studies, the route of administration, the distinction of the level of risk 
between trimesters, or the drug efficacy.[3;47] Therefore they became of limited usefulness 
for clinical decision making in pregnant women who need medical attention.[76] The FDA 
is currently revising its pregnancy labeling system to replace the letter categorization with 
texts that are complete and accurately offer the available information.[3] 
 
In order to avoid some of the cons of the FDA rating system, other rating systems 
were proposed like the Teratogen Information System (TERIS) rating system, which gives 
a drug summary on each drug, where each summary is “based on a thorough review of 
published data identified through MEDLINE, TOXLINE, and DART bibliographic 
searches. References provided in the Catalog of Teratogenic Agents [77], Drugs in 
Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risks [13], and 
Chemically Induced Birth Defects [78] are also used extensively”.[79] A potential 
advantage in the TERIS rating system is being based on the reproducibility, consistency, 
and biological plausibility of available clinical, epidemiologic, and experimental 
data.[47;79] In order to precisely cover the potential risk of a drug and to provide complete 
hazard information, the TERIS rating system gives 2 aspects for each exposure; the 
magnitude of teratogenic risk to a newborn after exposure, and the quality and quantity of 
data on which risk estimate was based. [79] 
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Not all SABA are rated by the TERIS system. The categorized SABA in the recent TERIS 
review which are Salbutamol, Levalbuterol, Metaproterenol and Pirbuterol are defined as 
having undetermined magnitude of risk to newborns, even Salbutamol which is considered 
the most trusted and used SABA. Also the quality and quantity of data on SABA are 
considered limited in the TERIS system. [47;79] LABA also have similar categorizations in 
TERIS system. Salmeterol has an undetermined magnitude of risk and very limited quality 
and quantity of data on it. Formoterol, being new in markets is still not rated by TERIS (not 
enough data for evaluation in the 2007 edition). [47;79] 
 
The risk of asthma symptoms during pregnancy, and the necessity of using asthma 
medications with unproven safety profiles during pregnancy has been a worrying issue in 
the past years until these days. Physicians managing asthma during pregnancy nowadays 
are placed in a substantial dilemma due to the difficulty of assessing the benefit-risk 
comparison in the pharmacologic therapy of asthma, especially when presently no asthma 
medication - as it is the case with every other medication - can be considered absolutely 
safe.[3;13;52;80] For that reason, asthma guidelines mostly recommend the use of all 
available information on a certain medication, rather than using its category in the different 
rating systems.[3] 
 
The endorsement of the use of SABA in the management of asthma during 
pregnancy came because of 3 facts; first, the known selectivity of beta2-agonists, second, 
their minimal systemic effects, and third, their well known safety profile in non-pregnant 
patients. [3;14] Salbutamol is considered the most important drug in this class. It has been 
used for many years in the management of asthma symptoms and exacerbations during 
pregnancy. Due to its efficacy, proven safety in  pregnancy,[3;14;81;82] and precedence in 
market, Salbutamol offered the chance for other SABA agents to be tried in pregnancy i.e. 
Fenoterol and Pirbuterol.[3] 
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LABA have been introduced in the 1990s as a breakthrough in asthma therapy. 
Their introduction has been considered as a major therapeutic development, and has lead to 
basic relocations of beta2-agonists use in the management of asthma.[72] Salmeterol and 
Formoterol are considered two highly selective LABA and the only prescribed in Canada. 
[3;72] According to guidelines of management of asthma during pregnancy,[3] there is only 
limited observational data on the use of LABA during pregnancy. However, they justified 
their recommendation for their use on the expected similar safety profiles between SABA 
and LABA.[3;40] Both Salmeterol and Formoterol are available in markets in separate 
forms or in combinations with ICS. Salmeterol has a longer history of use due to its 
precedence over Formoterol (since 1990), while Formoterol was approved by the FDA and 
Health Canada in 2001. Besides having limited human data on their safety during 
pregnancy,[3] both Salmeterol and Formoterol have shown fetal risk in animal models, with 
delayed fetal ossification and other adverse outcomes at high doses [83], and those may 
have contributed to their positioning in class C in the FDA category system. The 
recommendations of the guidelines do not elaborate on which LABA is preferred, however 
they mentioned the longer history of salmeterol in the markets as a point of advantage.[3] 
  
2.5 Beta2-agonists and Congenital Malformations 
To this date, we identified 15 studies which examined the association between 
beta2-agonists and congenital malformations (see Table 5).[14;26-39] Among them, nine 
examined beta2-agonists as a group (SABA and LABA),[28-34;37] seven examined SABA 
separately,[14;26;27;33-36] and six examined LABA separately (see Table 
5).[26;27;33;35;36;39] One of the major factors that could affect the strength of any of 
these studies is the type of the reference group used as a comparison group. Comparing 
beta2-agonists pregnant users against a group of non-asthmatics could potentially affect the 
results of a study since the observed relation will be confounded by the effect of asthma 
disease itself. Therefore, better conclusions could always be withdrawn from studies that 
  
 
28
compared beta2-agonists users with asthmatic non-users in order to separate as much as 
possible the effect of the medications and the disease. Another potential benefit that could 
be withdrawn through using an asthmatic non-users reference group is the reduction in the 
effect of the indication bias. Most of studies examining asthma medications are susceptible 
to indication bias due to asthma severity/control level, and using a reference group of 
asthmatic patients could relatively decrease the magnitude of such bias. Examining the fetal 
adverse effects of SABA and LABA combined as a group (beta2-agonists) may not be as 
informative and conclusive as separating SABA and LABA alone due to their different 
nature and different indications. However some important safety results could be obtained 
from such studies when separating both groups is unachievable. 
2.5.1 Short acting beta2-agonists (SABA) 
From the 7 studies that examined SABA separately from LABA, three studies used 
a reference group of asthmatic non-users.[14;35;36] A matched case-control study by 
Tamasi et al.[36] using self-reported questionnaires found a significant increased risk of 
any malformation with Fenoterol exposure compared to asthmatic pregnant women who 
were not exposed to Fenoterol anytime during pregnancy (pOR, 1.6; 95% CI, 1.3-2.0) (see 
Table 5). The authors classified the cases and controls according to the type of medication 
used during pregnancy, and the sample size (511 cases and 757 controls) helped to acquire 
relatively high statistical power in most groups (98% with Fenoterol exposure). The authors 
selected two or three newborns without congenital malformations and matched them with 
every case according to sex, birth week, and district of parent’s residence. Even if the 
authors compared asthmatic SABA users against a group of asthmatic non-users of SABA, 
the study has other limitations: (1) non adjustment for asthma severity, (2) neglecting 
potential confounders such as other maternal diseases or medications use during pregnancy, 
(3) the exposure to SABA was defined as anytime during pregnancy, and (4) selection bias 
possibility due to the inability to follow up non-respondent control mothers (75%)  
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Two other studies examined SABA use during pregnancy and the risk of major 
malformations using a reference group of asthmatic pregnant women which is considered a 
substantial advantage over other studies. [14;35]  Schatz et al. assessed the safety of any 
SABA during pregnancy in relation to fetal development.[14] Major and minor congenital 
malformations, among other outcomes, were analyzed and reported separately for anytime 
use during pregnancy and 1st trimester use (see Table 5). The authors in the study controlled 
for asthma severity based on medication requirement, smoking, use of other asthma 
medications, and the data were prospectively gathered for the SABA group and the 
asthmatic control group. For anytime and first trimester use of SABA during pregnancy, 
they found a cOR of 0.6 and 0.73 respectively, with a p-value > 0.05 for both (see Table 5). 
However, this study had some limitations: (1) the sample size was small and the study had 
only 9.7% power to detect the observed cOR of 0.73 in the 1st trimester and (2) the asthma 
severity aspect was assessed based on a medication requirement scale which is incomplete 
since many other factors could also indicate severity, such as asthma exacerbations and the 
need for acute care. The authors suggested the safe use of SABA during pregnancy but that 
conclusion needs more ascertainment.  
Tata et al. in a matched case control study examined the risk of major 
malformations with the maternal use of any SABA anytime during pregnancy and in the 1st 
trimester.[35] The authors used a reference cohort of asthmatic pregnant non-users. The 
study found an aOR of 1.06 (p-value 0.336) with SABA exposure anytime during 
pregnancy, and 1.01 (p-value 0.941) in the 1st trimester (see Table 5). The sample size of 
the study was relatively high but the statistical power to detect the aOR of 1.01 was low 
(17%). The study suffered a major limitation of using general population as a reference 
group. 
Other studies were identified and found using a reference group of non-asthmatic 
pregnant women or a mixed group of asthmatics and non- asthmatics. [26;27;33;34] Kallen 
and Olausson, in a retrospective cohort study based on the Swedish Medical Birth 
Register,[26] reported a slight increased risk of all types of congenital malformation with 
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maternal use of Terbutaline (SABA) (aOR 1.11, 95% CI 1.04-1.19), while no significant 
increased risk was found with Salbutamol (aOR 1.09, 95% CI 0.97-1.75)  comparing users 
of the medication  against non-users or general population (see Table 5). However, the 
study included the general population in the reference group.  Restricting analysis on any 
cardiovascular defects, only Salbutamol had a significant increased risk (OR=1.38, 95% 
CI=1.12-1.70). The study has some limitations including (1) use of the general population 
as a reference group, and (2) the accurate time of exposure during pregnancy wasn’t 
adequately determined. 
Another 2 studies by Shao Lin et al.[33;34] reported an increased risk of major 
malformations with SABA use; however the reported ORs in both studies were non-
statistically significant. Shao Lin et al.[33] examined the risk of gastroschisis, a major para-
umbilical abdominal wall defect, due to maternal asthma drug use in a case-control study 
and found an increased risk with Salbutamol and/or Pirbuterol (cOR 1.62, calculated using 
provided data in the study) (see Table 5). However SABA users were compared to non-
users, whether or not they had asthma. Also due to the interview methods drawbacks as 
being completed 6 weeks to 2 years after the delivery, recall bias may have occurred since 
mothers of affected children may be more likely to report their exposures than mothers of 
controls.  
Shao Lin et al. in another study [34], examined the association between asthma 
medications and the risk of congenital heart defects. The study was a matched case-control. 
The authors examined the risk of heart malformations due to maternal exposure to 
salbutamol and metaproterenol. An aOR of 2.37 with 95% CI 0.9-6.23 was found with 
salbutamol exposure in the 1st trimester. The power to detect this OR was 51% (see Table 
5). With metaproterenol exposure, a cRR of 1.35 was found. However the study suffered 
from some limitations: (1) the unexposed group was a group of non asthmatic women (2) 
non controlling for frequency of medication use or dose, (3) inaccurate reporting of 
exposure time during pregnancy, (4) possibility of recall bias due to the prior knowledge of 
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the presence of a major congenital malformations among cases, and (5) possibility of 
selection bias as the response rate was below 60%. 
Kallen and Olausson in another study examined the risk of any malformations with 
maternal use of SABA during pregnancy using the Swedish Medical Birth Register.[27] 
The authors examined the risk of any cardiovascular defect with maternal use of salbutamol 
and terbutaline anytime during pregnancy, the reported aOR were 0.93 (95% CI 0.64-1.36) 
with salbutamol and 1.14 (95% CI 0.93-1.38) with terbutaline (see Table 5). Yet the study 
suffered some limitations: (1) using a reference group of non-users (asthmatic and non-
asthmatic pregnant women), (2) the timing of exposure was not precise (anytime during 
pregnancy), (3) little information were gathered on the doses of SABA used during 
pregnancy, (4) low statistical power with the reported aORs (3.7% and 24%) and (6) 
multiple comparison tests problem. 
 
2.5.2 Long acting beta2-agonists (LABA) 
Six studies examined the association between LABA use during pregnancy and 
congenital malformations in newborns. Only three of them used a reference group of 
asthmatic pregnant women in order to separate the effect of LABA from asthma disease 
itself.[35;36;39] However, neither one of the six studies that investigated LABA found a 
significant increased risk of malformations with their use (see Table 5). 
Tata et al. in a matched case-control study using a reference group of asthmatic 
pregnant non-users reported an aOR of 1.12 with the use of any LABA anytime during 
pregnancy and aOR of 1.09 in the first trimester (see Table 5),[35] however both results 
were non-significant, and the study suffered some limitations which were discussed above. 
Shao Lin et al. in a case-control study found a non-significant cOR of 1.97 with Salmeterol 
use during the first trimester of pregnancy, compared to a group of asthmatic pregnant non-
users of LABA.[33] Kallen and Olausson in a retrospective cohort study reported no 
increased risk of any malformations with maternal use of Salmeterol and Formoterol during 
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the first trimester of pregnancy (aOR 1.02 95%CI 0.83-1.25) and (aOR 1.06 95%CI 0.80-
1.40) respectively (see Table 5).[26] The same authors in another study reported a non-
statistically significant increased risk of any cardiovascular defect with Salmeterol use in 
early pregnancy (aOR 1.50 95%CI 0.90-2.53) comparing Salmeterol users with non-users 
asthmatic and non-asthmatic women.[27] The limitations of these studies were discussed 
earlier. 
Tamasi et al. in a matched case-control study found no increased risk of any 
malformations with Clenbuterol use at anytime during pregnancy (pOR 0.7, 95%CI 0.50-
1.20) (see Table 5).[36] The authors compared Clenbuterol users to a group of asthmatic 
pregnant non-users. It is worth noting that Clenbuterol is not commonly used for 
controlling asthma symptoms as Salmeterol or Formoterol. The limitations of this study and 
the matching criteria were discussed earlier. Jones et al. investigated the adverse maternal 
and fetal risks due to exposure to LABA during pregnancy, mainly Salmeterol. Since only 
an abstract is available, few data could be obtained.[39] The authors compared a group of 
asthmatic pregnant women using Salmeterol (126 patients) with a group of pregnant 
women who used SABA only (91 patients), and another group of non-asthmatic pregnant 
women (115 patients) (see Table 5). There were no statistically significant differences 
observed in the prevalence of major congenital malformations between the three groups, 
with 4.7% in Salmeterol group, 3.9% in SABA group, and 1.9% in non-asthmatic group. 
The power of the study was 5.6% for the SABA group, and 22% for the non-asthmatic 
group compared to Salmeterol users group. The authors suggested that Salmeterol is not a 
human teratogen, but we need more data about the study procedures, conducting and 
analysis to be able to judge the adequacy of the conclusion. 
Three different prescription-based observational studies (Prescription-Event 
Monitoring) reported some cases of congenital malformations after maternal exposure to 
Salmeterol or Formoterol.[84-86] Wilton et al. reported two cases of congenital 
malformations among 25 births after maternal exposure to formoterol (see Table 5).[84] 
Wilton et al. in another study and Mann et al. reported 1 case of malformation among 47 
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babies and 1 case of congenital malformations among 65 pregnancies respectively, for 
mothers who have been exposed to Salmeterol (see Table 5).[85;86]  
 
2.5.3 SABA & LABA 
Nine studies examined SABA and LABA together as one group and their 
association with increased risk of congenital malformations. Shao Lin et al. reported in two 
studies a significant increased risk of major malformations with maternal use of beta2-
agonists in the first trimester comparing beta2-agonists users with non-asthmatic pregnant 
women (see Table 5).[33;34] In the first study, the authors found an increased risk of 
various heart defects with maternal use of any beta2-agonists during the first trimester of 
pregnancy, with an aOR of 2.2 (95% CI 1.05-4.61).[34] The authors examined in the 
second study the association between beta2-agonists and the risk of gastroschisis, which is a 
major para-umbilical abdominal wall defect (see Table 5).[33] The authors found an 
increased risk of gastroschisis in newborn of women reported using beta2-agonists during 
the first trimester with aOR 2.06 (95%CI 1.19-3.59) as compared to asthmatic and non-
asthmatic non-users of beta2-agonists. However, both studies suffered from indication bias 
and other limitations that were discussed earlier. 
 
Four studies among the 9 that investigated beta2-agonists used a reference group of 
asthmatic pregnant women (see Table 5).[29-32] Bakhireva et al. in a prospective cohort 
study examined the association between maternal use of beta2-agonists and fetal outcomes, 
including major malformations (see Table 5).[31] Comparing beta2-agonists users against 
asthmatic ICS users, the authors didn’t find any increased risk of malformations (cRR 
0.95). The prospective cohort design used limited the possibility of participation, selection, 
and recall bias and only 5% of the participants were lost in the follow-up. However, the use 
of self-reporting medication use method in this study has a minor limitation. Due to the 
recruitment of patients from different multiple geographic areas with different types of 
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insurance coverage and multiple prescription sources, the supplementation of patient report 
information with pharmacy records was unachievable. Also self-reports were validated 
against medical records only for the portion of patients with available data. 
 
Schatz et al. in an observational cohort study examined the association between 
beta2-agonists use anytime during pregnancy and adverse perinatal outcomes including 
major congenital malformations.[30] The authors didn’t find an increased risk of 
malformations with beta2-agonists use (cRR 1.0) compared to asthmatic non-users (see 
Table 5). The study reflected the contemporary use of beta2-agonists nowadays, and asthma 
severity and control together with other potential covariables were adjusted for in the study. 
However the sample size was insufficient to guarantee high statistical power. Alexander et 
al. in a retrospective cohort study examined the association between beta2-agonists use 
during pregnancy and perinatal outcomes (see Table 5).[29] The authors compared beta2-
agonists users against a group of asthmatics taking no medications, and another group of 
asthmatics using ICS. The study didn’t find an increased risk of any malformations with 
beta2-agonists use with aOR 0.9 (95%CI: 0.6-1.4) and aOR 0.8 (95%CI: 0.4-1.7). Yet the 
study suffered some limitations: (1) no adjustment for asthma severity and control, (2) 
small sample sizes and limited power (12% for both comparisons), (3) the exposure was not 
specific to the first trimester and was measured during the entire pregnancy, and (4) no 
information on the doses of medication use. Clark et al. in a prospective cohort study 
examined the association between beta2-agonists use during pregnancy and neonatal 
outcomes, including any malformations (see Table 5).[32] The authors compared beta2-
agonists users with a group of asthmatic ICS users, and another group of asthmatics using 
both types of medications. The study didn’t find any increased risk of malformation with 
beta2-agonists use anytime during pregnancy. The authors however didn’t adjust for asthma 
severity/control, the sample sizes were insufficient to obtain high statistical power, the 
exposure was not specific to the first trimester and was measured during the entire 
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pregnancy, and the data were gathered from participants of one center which may affect the 
generalizability of the study results. 
 
Schatz et al. in a prospective cohort study examined the safety of beta2-agonists 
among other asthma and allergy medications.[28] The study compared beta2-agonists users 
with non-asthmatic pregnant women. No increased risk of major congenital malformations 
was found with maternal use of beta2-agonists anytime during pregnancy or during the first 
trimester (cRR 0.6, p-value >0.05) and (cRR 0.76, p-value >0.05) respectively (see Table 
5). The use of a non-asthmatic reference group prevented from separating the medication 
effect alone, and the small sample sizes resulted in low statistical power for the study 
(17%). Lao et al. in a retrospective cohort study examined the association between beta2-
agonists and any malformations.[37] The study didn’t find any increased risk with beta2-
agonists use anytime during pregnancy comparing asthmatic beta2-agonists users with non-
asthmatic pregnant women. However, the sample sizes in the study were very small, and 
the exposure was not specific to the first trimester and was measured during the entire 
pregnancy. Olesen et al. in a population-based prescription study examined the risk of 
congenital malformations among other adverse neonatal outcomes with maternal exposure 
to different asthma medications including beta2-agonists.[38] Data on the exact numbers 
and results were not shown in the study; however the risk of malformations was assessed 
for asthmatic beta2-agonists users receiving prescriptions for beta2-agonists 30 days prior to 
conception until 8 weeks of gestation. The authors used a reference group of women who 
didn’t purchase any prescription drug during pregnancy. The authors reported no deviations 
from the expected values regarding the risk of malformations with maternal use of beta2-
agonists. The study suffered some limitations, including; (1) no available data on hospital 
admission medications, and (2) no adjustment for other maternal diseases and conditions 
during pregnancy. 
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From the former illustration, it is obvious that drawing rightful and precise 
conclusions from the literature on the risk of congenital anomalies due to beta2-agonists use 
during pregnancy is difficult and requires carefulness and assertion. The former studies 
suffered from common limitations; (1) using a reference group of non-asthmatic pregnant 
women, (2) inadequate adjustment for asthma severity and control, (3) inaccurate defining 
of exposure time during pregnancy, and (4) small sample sizes and low statistical power. 
Hence, for the previously mentioned reasons, we aimed to conduct a large population-based 
study in order to assess the association between beta2-agonists and congenital 
malformations, while trying to avoid the limitations of other studies. 
 
  
Table 5. Description of the studies that examined beta2-agonists and their association with major and any malformation 
ß2 agonist No*
Outcome (% or 
mean) Type of exposure No*
Outcome (% or 
mean OR or RR
(95% CI) or (P 
Value)
Outcomes
Major 
Malformations
Any 103 3.9 Non Asthmatic 303 0.3 cRR 13 NA 72.5 8
Any 103 3.9
Asthamtic ICS 
users £
438 4.1 cRR 0.95 NA 4.8 16.7
Schatz et al. 2004 
(30)
Observational Cohort 
+ RCT
Maternal/Fetal medical 
centers(patient history+monthly 
visit+postportum reviews) 1994-
2000
Any time Any 1828 2.0 Ω
ß2 agonist non 
users §Ŧ¥
295 2.0 Ω cRR 1.0 (p>0,05) 5 12.2
Any time Any ‡ 667 3.7 823 6.2 cRR  0.6 (p>0,05) 59.1 53.9
1st trimester Any ‡ 488 4.3 1000 5.6 cRR 0.76 (p>0,05) 17.5 47.6
Exp. NE Exp NE
Shao lin et al. 2009 
(34)
Matched Case Control 
2:1
NY state congenital malform. 
Registry+medical 
records+tel.interviews 1988-1991
1st trimester Any ¢ 22 443 22 965
Non Asthmatic, 
No asthma Med aOR 2.2 (1.05,4.61) 60 19.4
cOR 1.94 (1.14,3.29) 71 28
aOR 2.06 (1.19, 3.59) ___ ___
358 96 3932
Non user µ 
(asthmatic/non 
asthmatic)
Shao Lin et al. 
2008 (33) Case Control
National birth defects prevention 
study(clinics)+tel.intervews+prescrip
tion database 1997-2002
1st trimester Any µ 17
Schatz et al. 1997 
(28)  Prospective Cohort
Medical care 
program(Questionnaire/daily cards) 
1978-1989
Non Asthmatic  
Non user
Case Control Studies
Cases Controls
NE Pop. type
Bakhireva et al. 
2005 (31) Prospective Cohort
Org.of teratology inf. 
Services(tel.interviews+records) 
1998-2003
Any time
Non specified (Both SABA and  LABA)
Study Design Data collection Exposure Time
ß2 agonist users Control Effect Power (%) for 
study's effect 
size
Power (%) 
for RR =1.5
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ß2 agonist No.*
Outcome (% or 
mean)
Type of exposure No* Outcome (% or 
mean
OR or RR (95% CI) or (P 
Value)
Outcomes
Major 
Malformations
Any time Any S.A. §¢# 259 3.9 295 6.4 cOR 0.6 (p> 0,05) 25.8 24.9
1st trimester Any S.A. §¢# 180 3.9 295 6.4 cOR 0.6 (p> 0,05) 25.8 22.3
Any time Any S.A. §¢# 259 3.9 101 6 cOR 0.65 (p>0,05) 16.2 11.9
1st trimester Any S.A. §¢# 180 3.9 172 5.3 cOR 0.73 (p> 0,05) 9.7 15.1
Any time Any S.A. §¢# 259 3.5
General 
population
1999254 3.0 NA NA 9.6 31
Exp. NE Exp NE
1st trimester 15 443 14 965 Non Asthmatic 
No asthma Med.
aoR 2.37 (0.9,6.23) 51 14.5
Early pregnancy 17 15 18 25 Non Asthmatic 
No asthma Med.
cRR 1.3 (p>0,05) __ __
Alupent 
(Metaproterenol)µ
1 31 1 42
Non Asthmatic 
No asthma Med. cRR 1.35 NA __ __
Terbutalin µ 1 31 0 43
Non Asthmatic 
No asthma Med. __ NA __ __
Any time 375 4420 2085 26235
Asthmatic non 
users aOR 1.06 
p (0.336) 
(0.94,1.19) 16.9 100
1st trimester NA NA NA NA NA aOR 1.01 
p (0.941)    
(0.86-1.18) NA NA
 Non user µ 
(asthmatic/non 
asthmatic)
368 88 91 26
Tata et al. 2008 
(35)
Matched Case Control 
1:6
Health improvement Database 1988-
2004 Any S.A.
4033 cOR 1.62 NA13
Shao lin et al. 2009 
(34) Matched Case Control
NY state congenital malform. 
Registry+medical 
records+tel.interviews 1988-1991
Vent.µ
1st trimester
Shao Lin et al. 
2008 (33)
Case Control
National birth defects prevention 
study(clinics)+tel.intervews+prescrip
tion database 1997-2002
1st trimester Albut./Pirbuterol µ
Case Control Studies
Cases Controls
NE Pop. type
Schatz et al. 1988 
(14) Prospective Cohort
Medical care 
program(Questionnaire:history of 
asthma)+medical records 1978-1984
Non Asthmatic
Asthamtic non 
users µ
Control Effect Power (%) for 
study's effect 
size
Power (%) 
for RR=1.5 
 SHORT ACTING (SABA)
Study Design Data collection Exposure Time
ß2 agonist users
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ß2 agonist No.*
Outcome (% or 
mean)
Type of exposure No* Outcome (% or 
mean
OR or RR (95% CI) or (P 
Value)
Outcomes
Major 
Malformations
Asthmatic SABA 
users 91 3.9 NA NA 5.6 9.1
Non Asthmatic 115 1.9 NA NA 22 7.4
Exp. NE Exp NE
Shao Lin et al. 
2008 (33)
Case Control
National birth defects prevention 
study(clinics)+tel.intervews+prescrip
tion database 1997-2002
1st trimester Salmet.µ 2 379 11 4110
Non user µ 
(asthmatic/non 
asthmatic)
cOR 1.97 NA 14 6.8
Any time 25 4420 131 26235 aOR 1.12 P (0.614)      
CI (0.72,1.75)
8.6 48.6
1st trimester NA NA NA NA aOR 1.09
P (0.77)       
CI (0.62,1.9)
__ __
Asthmatic non 
users
Tata et al. 2008 
(35)
Matched Case Control 
1:6
Health improvement Database 1988-
2004 Any L.A.
126 4.7
Case Control Studies
Cases Controls
NE Pop. type
Effect Power(%) for 
study's effect 
size
Power (%) 
for RR=1.5
Jones et al. 2002 
(39) Prospective cohort
Org. of teratology Inf. Services 1998-
2001 Any time Salmet.
 LONG ACTING (LABA)
Study Design Data collection Exposure Time
ß2 agonist users Control
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ß2 agonist No.*
Outcome (% or 
mean)
Type of exposure No* Outcome (% or 
mean
OR or RR (95% CI) or 
(P Value)
Outcomes
All 
Malformations
Non Asthmatic 717 2.2 cRR 1.0 ∫∫ NA __ __
Asthamtic ICS 
users £
370 0.8 cRR 2.8 ∫∫ NA __ __
ß2 agonist + ICS 170 3.5 cRR 0.63 ∫∫ NA __ __
Non Asthmatic 13709 7.7 aOR 1 (0.6,1.6) 9.2 58
Asthmatic No Med. 375 6.9  aOR 0.9 (0.6,1.4) 12.5 31
Asthmatic ICS µ 139 6.2 aOR 0.8 (0.4,1.7) 12 15.5
Non Asthmatic 54 0 NA3.8
Alexander et al. 
1998 (29)
Retrospective 
Cohort
NA __ __Lao et al. 1990 (37)
Retrospective 
Cohort
Hospital and clinical database 
1984-1987 Any time Any
 §╪ 54
Perinatal database and hospital 
records 1991-1993
Not determined Any 303
2.2
8.5
Clark et al. 2007 
(32) Prospective Cohort
Clinics 
(Questionnaire/database)+neon
atal details 2001-2003
Any time Any 178
Non specified (Both SABA and LABA)
Study Design Data collection Exposure Time
ß2 agonist users Control Effect Power (%) for 
study's effect 
size
Power (%) 
for RR =1.5
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ß2 agonist No.*
Outcome (% or 
mean)
Type of exposure No* Outcome (% or 
mean
OR or RR (95% CI) or 
(P Value)
  Outcomes
All 
Malformations
Salbut. 271 NA NA NA aOR  1.09 (0.97,1.75) __ __
Terbut 857 NA NA NA aOR  1.11 (1.04,1.19) __ __
Exp. NE Exp NE
Salbut. 45 466 77 680 pOR 0.9 (0.6, 1.3) 8 68
Terbut. 179 332 241 516 pOR 1.2 (0.9, 1.5) 35.6 94.5
Metaproterenol 3 508 6 751 pOR 0.7 (0.2, 3.0) 6.3 13.1
Fenoterol 328 183 403 354 pOR 1.6 (1.3, 2.0) 98.9 95.7
Salbut. 29 4986 3446 574284
cOR 0.97     
aOR 0.93 (0.64, 1.36) 3.7 77
Terbut. 104 4911 10613 567117
 cOR 1.13    
aOR 1.14 (0.93, 1.38) 24 99
Non user 
(asthmatic) 
Kallen et al. 2003 
(27) Case control
Swedish Medical birth 
Register(questionnaire by 
midwives+medical records) 
1995-2001
Early pregnancy
Non user 
(asthm./non 
asthm.) 
Tamasi et al. 2006 
(36)
Matched Case 
control 1:3
Hungarian congenital 
abnormality registry (self- 
reported questionnaire) 1980-
1996
Any time
Control
Case Control Studies
Cases Controls
NE Pop. type
Exposure Time
Power (%) 
for RR=1.5 
Kallen et al. 2007 
(26)
Retrospective 
Cohort
Swedish Medical birth Register 
1995-2004 1
st trimester
General 
pop.(asthm./non 
asthm.)
ß2 agonist users
 SHORT ACTING (SABA)
Effect Power (%) for 
study's effect 
size
Study Design Data collection
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ß2 agonist No.*
Outcome (% or 
mean) Type of exposure No*
Outcome (% or 
mean OR or RR
(95% CI) or 
(P Value)
   Outcomes
All 
Malformations
Salmet. 97 NA NA NA NA aOR  1.02 (0.83,1.25) __ __
Formot. 52 NA NA NA NA aOR  1.06 (0.80,1.40) __ __
Wilton et al. 2002 
(84)
Observational 
cohort
Prescription-event 
monitoring(prescription 
data+questionnaire to 
practicioners) 1996-1998
1st trimester Formot.
31 Preg. (25 
births) 2 Cases NA NA NA NA NA __ __
Wilton et al. 1998 
(85)
Observational 
cohort
Prescription-event monitoring 
(priscriptions 
data+questionnaire to 
practitioners) 
1st trimester Salmet. 47 (births) 1 Case (2.13%) NA NA NA NA NA __ __
Mann  et al. 1996 
(86)
Observational 
cohort
Prescription-event monitoring 
(priscriptions 
data+questionnaire to 
practitioners) 
Any time Salmet. 65 1 Case (1.53%) NA NA NA NA NA __ __
Exp. NE Exp NE
Tamasi et al. 2006 
(36)
Matched case 
control  1:3
Hungarian congenital 
abnormality registry (self- 
reported questionnaire) 1980-
1996
Any time Clenbuterol 28 483 56 701 Non user 
(asthmatic) 
pOR 0.7 (0.5, 1.2) 33.3 56.7
Kallen et al. 2003 
(27)
case control
Swedish Medical birth 
Register(questionnaire by 
midwives+medical records) 
1995-2001
Early pregnancy Salmet. 15 5000 1137 576593
Non user 
(asthm./non 
asthm.) 
cOR 1.52     
aOR 1.5
(0.90, 2.53) 36.7 34.5
Case Control Studies
Cases Controls
NE Pop. type
Kallen et al. 2007 
(26)
Retrospective 
Cohort
Swedish Medical birth 
Registry 1
st trimester
 LONG ACTING (LABA)
Study Design Data collection Exposure Time
ß2 agonist users Control Effect Power (%) for 
study's effect 
size
Power (%) 
for RR=1.5
 
  
Women participating in the different studies were asthmatic unless stated otherwise. 
 
ICS: inhaled corticosteroids; Vent : Ventolin; Albut.: Albuterol; Terbut.: Terbutalin; 
Salmet.: Salmeterol; Formot.: Formoterol;  S.A.: Short acting beta2-agonist; L.A.; Long 
acting beta2-agonist; RCT: randomized controlled trial; org. of teratology inf. services: The 
Organization of Teratology Information Services (OTIS); Med.: medications; aOR: adjusted 
odds ratio; cOR: crude odds ratio; cRR: crude risk ratio; cMD: crude mean difference; aMD: 
adjusted mean difference; pOR :crude prevalence odds ratio; Exp.: exposed; NE : non 
exposed; NE pop. type: non exposed population type; NA: data unavailable; – : power or 
effect size impossible to calculate. 
 
* Number of pregnancies unless stated otherwise. 
§ Women may have concurrently received inhaled corticosteroids. 
# Women may have concurrently received asthma controller medications (cromolyn). 
¢ Women may have concurrently received asthma controller medications (theophylline). 
£ Women may have concurrently received short-acting beta2-agonists (inhaled or systemic). 
µ Women may have concurrently received any other type of asthma medication. 
‡ Women may have received inhaled, oral or injectable beta2-agonists. 
∫∫ Matching was performed and not considered in crude calculations. 
 
2.6 Risk Factors for Congenital Malformations 
2.6.1 Etiology 
Congenital malformations’ etiology has been the object of medical research for 
many years. It is believed now that the causes of birth defects could be genetic, 
environmental, or unknown.[87-90] However, the etiology of most human malformations 
is still unknown.[89] The genetic causes represent 15-25%, including chromosomal 
abnormalities and new mutations.[89;90] On the other hand, the environmental causes 
includes maternal diseases, infectious agents, teratogenic drugs, alcohol, smoking and 
radiations, all together representing about 10-15% of congenital malformations.[91] 
Finally, with about 65-75 % of unknown causes, multifactorial gene-environment 
interactions is one of its most significant proportions composing about 20-25% of the 
unknown malformations.[87-90] In the following sections we will discuss some of the 
important risk factors of congenital malformations that are closely related to our research 
objectives. 
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2.6.2 Maternal characteristics 
Maternal age is considered one of the major factors that could affect pregnancy 
outcomes including malformations.[92-94] It is believed nowadays, based on several 
studies, that women at the extremes of the age distribution (< 20 years or > 35 years) have 
an increased risk for congenital malformations compared to women in the mid-age (21-29 
years).[92;94] While it is extensively proven that infants of older mothers have a higher 
risk of chromosomal anomalies, such as Down syndrome, the true risk of non-
chromosomal anomalies is still equivocal.[92-94] The area of residence, urban or rural, has 
been shown to be associated with differences in perinatal outcomes and congenital 
malformations. The urban/rural status can greatly affect associations with certain birth 
defects, reaching more than two folds increase in relative risk of certain birth defects 
among rural residents.[95-97] Social position-presented by maternal education level and 
socioeconomic status-has been associated with different perinatal and fetal health 
outcomes including congenital malformations.[98-101] An increased prevalence of 
congenital malformations has been reported for women with lower social position, as 
compared with better-off women.[98;99;102] In a recent study, Women with less than 10 
years of schooling had an almost three-fold increased risk of giving birth to a baby with a 
congenital anomaly as compared with women who had more than 4 years of higher 
education[102], and these results were consistent with other studies in 
literature.[98;100;101;103] 
 
2.6.3 Medication use during pregnancy 
Prescription and over the counter drugs are considered part of the environmental 
causes of congenital malformations with contribution of less than 1%, however congenital 
anomalies caused by environmental factors are of special importance as they are 
potentially preventable.[89;104] 
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The maternal exposure to certain environmental cause of malformation lies under 
the umbrella of teratology, with term “teratogen” being used to denote an agent that can 
produce structural or functional abnormalities in an exposed embryo or fetus.[89;104] 
Moreover, the dose, route of exposure, stage of pregnancy when the exposure to teratogen 
occurred plays the major role in identifying and labelling teratogens, so the list of 
teratogens only indicates teratogenic potential.[88;89;104] One of the important principles 
in studying teratogens is that an exposure to one is said to be following a toxicologic dose-
response curve, where there is a threshold below which no effect will be observed. 
[88;89;104] Also as the dose of the teratogen increase, both severity and frequency of the 
adverse fetal effect increase.[89] Another potential principal to consider is determining the 
length of the exposure and the embryonic stage, since some teratogenic effects have broad 
period of sensitivity while others have very narrow periods.[88;89;104] 
 
During pregnancy, many exposures may raise the concern of potential 
teratogenicity. Complete information on hundreds of exposures is present in clinical 
teratology knowledge bases such as TERIS and in reference text books.[13;77;79] 
More than 80% of pregnant women take prescription or over-the-counter (OTC) 
drugs during pregnancy.[105] Many prescription drugs, such as anticonvulsants, 
angiotensin converting enzyme inhibitors, antineoplastic agents, and hormonal agents have 
been proven to be teratogenic.[77;88;89] On the other hand, most of over-the-counter 
medications have undetermined risk ratings, [106-109] while others like Aspirin showed 
increased fetal risk of malformation.[107;109] Pregnant women use a variety of OTC 
medications, including analgesics, antihistaminics, antacids, a range of herbal preparations 
and more.[108;109] Yet, the important issue to consider is that prescription and OTC 
medications risks represent less than 1% of the congenital malformations in human, and 
they are potentially preventable.[88;89] 
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2.6.4 Maternal conditions and lifestyles 
The maternal disease states and different maternal conditions represent together the 
prime environmental cause of malformations (about 4%) [89], including different diseases 
like diabetes (gestational and chronic) [89;110], epilepsy [111;112], iodine deficiency [89], 
and intrauterine complications.[89] A wide range of malformations are caused by the 
previously mentioned maternal conditions, including major and minor types.[88]  
 
Maternal diabetes is a known risk factor for congenital malformations.[113] It has 
also been known for many years that good metabolic control in the preconceptional period 
decreases the risk of congenital malformations.[113] Maternal hyperglycemia is a non-
specific teratogen imposing the same risk of malformations to pregnant women with both 
type-1 and type-2 diabetes.[114] According to recent estimates, pregnancies complicated 
by pre-existing maternal type-1 and type-2 diabetes have an approximately twofold to 
fourfold increased risk of major malformations.[115-117]  
 
It has been known for several decades that the risk of major and minor 
malformations in infants of epileptic mothers is twice higher than in the general 
population.[111;118] This is partly attributable to the teratogenicity of the drugs used to 
treat epilepsy, but the disease in itself most probably increases the risk, while no 
epidemiological technique is ideal to separate the effects of the disease and the drugs on 
the fetus.[119;120] Whereas maternal epilepsy induces a two to three-fold increase in the 
risk of any kind of major malformations, four main types of defects are overrepresented in 
infants of epileptic mothers : orofacial clefts, cardiovascular defects, spina bifida and 
hypospadias.[120]  
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Maternal overweight and obesity are also proven to be associated with an increased 
risk of a range of congenital malformations.[121-124] Obese women were more likely to 
have an infant with spina bifida, omphalocele, heart defects and multiple anomalies. [121-
125] Overweight women were more likely to have infants with heart defects and multiple 
anomalies.[121-125] Maternal obesity often leads to diabetes which is itself associated 
with increased risk of birth defects.[121-125] 
 
Lifestyles and maternal habits like smoking and alcoholism should also be 
cautiously considered.[89] The maternal alcohol consumption, or binge drinking, can 
produce wide spectrum of birth defects, which range in frequency and severity from fetal 
alcohol effects to typical fetal alcohol syndrome.[13;89;104;106] Smoking during 
pregnancy has been associated with low birth weight, stillbirth, and intrauterine growth 
retardation.[13;88;89;104;106] Although there are many occasional reports of 
malformations in women who smoke during pregnancy, there is no consistent evidence 
that there is a significant increase in risk of malformation due to maternal smoking during 
pregnancy.[13;104;106] Furthermore, the occurrence of congenital malformations due to 
maternal exposure to tobacco or alcohol is believed to be a dose related 
association.[104;106]  
 
2.6.5 Fetal conditions and infections 
The presence of embryonic and fetal infections accrues for about 3% of the 
malformations in humans.[88;89] The list of proven fetal and embryonic infections with 
teratogenic effects includes Cytomegalovirus, herpes simplex virus, lymphocytic 
choriomeningitis virus, rubella virus, toxoplasmosis, syphilis, and varicella-zoster 
virus.[89;104] Since the early 1970s, these organisms and the resulting clinical syndromes 
have been categorized as TORCH infections, a useful acronym referring to Toxoplasrna 
gondii, Other microorganisms, rubella virus, Cytomegalovirus (CMV) and herpes 
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viruses.[126;127] Authors often added syphilis under “other microorganisms”.[127] Most 
of the TORCH infections cause mild maternal morbidity, however, they often present 
serious fetal consequences, and treatment of maternal infection frequently has no beneficial 
effect for the fetus.[126-128]Infants with congenital infection due to one of the TORCH 
agents may result in cardiac defects, occular lesions, hearing defects, central nervous 
system defects, neonatal purpuras, and hepatosplenomegaly.[126;127] 
 
2.6.6 Pregnancy related characteristics 
 Multiplicity is considered a known risk factor for congenital malformations. Many 
epidemiological studies have observed that multiple births have a higher risk of congenital 
malformations compared to singletons.[129-131] Central nervous defects, cardiovascular 
defects, alimentary tract defects, ear defects, respiratory defects have all been observed 
more often among multiple births.[129;130] Among the specific malformations detected 
frequently with multiple births are macrocephaly, encephalocele, hydrocephaly, cleft lip 
and palate, anomalies of the diaphragm, cardiac septal defects, atresia or stenosis of the 
large intestine or anus, tracheoesophageal fistula,malformations of the alimentary tract, 
inguinal and umbilical hernias, and cystic kidney.[129-131]  
There is considerable evidence that late birth order (parity order) is associated with 
certain congenital malformations, such as congenital heart diseases, neural tube defects, 
spina bifida, and orofacial clefts.[132-134] 
 
2.6.7 Asthma related variables 
The most important asthma related factors are the asthma severity/control (i.e. 
being mild, moderate or severe and controlled or uncontrolled), and the medications used 
to control the symptoms. The use of high doses of inhaled corticosteroids (ICS) and oral 
corticosteroids (OCS) are considered risk factors for congenital malformations.[61;135-
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137] Also the use of other asthma controller medications (leukotriene-receptor antagonists, 
Ipratropium, and Nedocromil), and intra-nasal corticosteroids (INCS) during pregnancy 
should be considered due to limited human data available for these 
medications.[13;61;135-138] Severe and uncontrolled asthma are potential risk factors for 
congenital malformations and should be adjusted for properly.[3;30;52;55] One of the 
credible measures to assess asthma severity and control which we used in our study is the 
validated indexes developed according to the Canadian Asthma Consensus Guidelines, 
where severity is classified into mild, moderate or severe and control into controlled or 
uncontrolled.[139]  Moreover, the emergency department (ED) visits for asthma, hospital 
admission for asthma, and the use of oral corticosteroids could act as a supporting mean for 
the measurement of asthma severity and control. [11;139] 
          
2.7 Potential confounders    
After evaluating the different risk factors of congenital malformations, we find that 
the evaluation of the fetal safety of beta2-agonists through examining their association with 
congenital malformations may be challenging due to the emergence of several potential 
confounders. In the analysis of the true risk of beta2-agonists on fetal adverse effects, we 
should take into consideration the risk factors discussed above, also other confounding 
variables that could be retrieved from the literature on asthma during pregnancy. A 
summary of the confounders will include: socio-demographic variables such as maternal 
age, receipt of social assistance during pregnancy, area of residence at delivery, and 
education level at delivery; 2) maternal and fetal conditions including chronic 
hypertension, pregnancy induced hypertension, diabetes mellitus, gestational diabetes, 
epilepsy, uterine complications during pregnancy, maternal exposure to teratogenic drugs 
in the 1st trimester, parity, multiplicity, and fetal infections; and 3) asthma-related 
variables including the use of inhaled corticosteroids, use of other asthma controller 
medications, use of intranasal and oral corticosteroids, and emergency department (ED) 
  
 
50
visit or hospitalization for asthma in the 1st trimester. In addition, asthma severity level and 
asthma control measured prior to pregnancy and during the first trimester are considered 
important potential confounders. 
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CHAPTER 3: OBJECTIVES 
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Objectives of our study 
3.1 General objective 
To investigate the association between maternal exposure to inhaled beta2-agonists 
during the first trimester of pregnancy and the risk of congenital malformations in 
newborns of asthmatic women. 
3.2 Primary objectives 
1. To evaluate the association between maternal exposure to SABAs and LABAs during 
the first trimester of pregnancy and major congenital malformations. 
2. To evaluate the association between maternal exposure to SABAs and LABAs during 
the first trimester of pregnancy and any congenital malformations. 
3.3 Secondary objectives 
1. To examine the association between maternal exposure to SABAs and LABAs during 
the first trimester of pregnancy and the risk of different specific congenital 
malformations. 
2. To explore whether or not there is a dose-response relationship between SABA use 
during the first trimester and the risk of congenital malformations.  
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CHAPTER 4: METHODS 
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This chapter encompasses the methods presented in the manuscript more comprehensively. 
 
4.1 Source of data 
  
 This study used data from asthmatic women through the linkage of three 
administrative health databases from the province of Quebec; Régie de l’assurance maladie 
du Québec (RAMQ), MED-ECHO, and the “Fichier des événements démographiques du 
Québec” (birth and death registries) administered by the Institut de la Statistique du 
Québec (ISQ). The RAMQ’s databases provide information on outpatient medical services 
dispensed to all Quebec residents and prescribed medications dispensed in community 
pharmacies. RAMQ’s Public Drug Insurance Plan for residents cover about 43% of the 
residents of Quebec [140] including the elderly, recipients of social assistance since 1980, 
and 1.7 new adherents since January 1997, who are mainly consisting of workers and their 
families not covered by a private drug insurance plan.  
 
MED-ECHO provides information on all acute care hospitalizations occurring in 
Quebec, including birth weight and gestational age for delivery hospitalizations. The 
Fichier des événements démographiques du Québec (ISQ) database provides demographic 
variables on the mother, father and baby as well as birth weight and gestational age. 
 
 Data recorded in the RAMQ public drug insurance plan database and the medical 
diagnosis for asthma recorded in the RAMQ Medical Services database have been formally 
evaluated and found to be valid and precise.[141;142] The RAMQ and MED-ECHO 
databases have often been used for research on asthma and pregnancy with many articles 
published in renowned medical journals.[11;135;138;143;144] 
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4.2 Study design 
To achieve our goal, a population-based retrospective cohort design was used. A 
cohort comprising pregnancies from asthmatic women insured by the RAMQ Public 
Drug Insurance Plan who gave birth between January 1, 1990 and December 31, 2002 
was formed. Using the gestational age and date of birth of the newborns recorded in the 
MED-ECHO and ISQ databases, we identified the date of the first day of the last 
menstrual period and the date of delivery for each pregnancy. The inclusion criteria 
were: 1) having at least one pregnancy ending in a delivery (live or still birth) between 
1990 and 2002; 2) being 12-50 years old at the beginning of the pregnancy; 3) having 
at least one diagnosis of asthma (ICD-9 code 493 except 493.2) and at least one 
prescription for an asthma medication at any point in time two years before  or during 
pregnancy itself; and 4) being covered by the RAMQ Public Drug Insurance Plan for at 
least one year before and throughout the pregnancy. Pregnancies of women taking oral 
beta2-agonists during the first trimester were excluded in order not to affect our 
exposure assessment (the use of the inhaled form of beta2-agonists), and those taking 
oral corticosteroids chronically in the year before conception were excluded, due to the 
previously proven increased risk of congenital malformations among women exposed 
to oral corticosteroids during pregnancy.[145-147] We also excluded pregnancies of 
women who were rheumatic cases, or suffering from Cushing disease, iodine 
deficiency, adrenal tumors, and folic acid deficiency, which are all rare diseases that 
can affect fetal development and may cause congenital malformations.[148] 
 
For each pregnancy in the cohort, we obtained from the RAMQ data on all 
prescriptions dispensed (name, date of filling, dose, quantity, dosage form, duration of 
the prescription, encrypted identification, and speciality of prescribing physician) and 
data on inpatient, emergency and hospital medical services; nature of medical act, date 
of service, site of practice [outpatient clinic, ED, and hospital], diagnosis code, 
encrypted identification, and speciality of the treating physician. RAMQ also provided 
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socioeconomic data; date of birth of mothers and children, receipt of social assistance, 
and area of residence of the mother during pregnancy. These data were obtained in the 
year preceding and during pregnancy for the mother and during the first year of life for 
the newborns. 
 
From MED-ECHO, data were obtained on all hospitalizations, including principal 
diagnosis, up to 15 secondary diagnoses, date of entry, and duration of hospitalization 
for the year before, during, and one year after pregnancy for the mothers. For delivery 
hospitalizations, gestational age and birth weight of the baby data were obtained in 
addition to other aforementioned data. Moreover, hospitalization data for the children 
during their first year of life were obtained. 
 
The Fichier des événements démographiques du Québec (ISQ) contained data 
about the level of education of the mother and the parity of the ongoing pregnancy.  
 
An authorization was obtained from the Commission d’accès à l’information du 
Québec before requesting and linking the information from RAMQ, MED-ECHO, and 
ISQ databases. 
 
4.3 Outcome definition 
The presence of a congenital malformation was identified within the cohort using 
diagnosis codes specific to congenital malformations (International Classification of 
Diseases-9th revision codes, ICD-9: 740-759 and 778.6) (see table 6) obtained from the 
RAMQ and MED-ECHO databases, either from the mother’s or the infant’s records. 
Our list of congenital malformations was compared with the list provided by the 
Collaborative Perinatal Group[149] and verified by a geneticist from the CHU Saint-
Justine for exactness and completeness. An infant was identified as a case if he or she 
had at least one diagnosis of a congenital malformation at birth or during the first year 
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of life recorded in the RAMQ or MED-ECHO databases. Classification of congenital 
malformations into major or minor was performed by the geneticist. A congenital 
malformation was classified as major if it could be life-threatening or cause major 
cosmetic defects. If a malformation could be classified as either minor or major, it was 
considered as major if there was at least one hospitalization related to the malformation 
during the first year of life.  
 
The primary outcomes were major and any congenital malformations and the 
secondary outcomes were different specific congenital malformations, which were 
anencephalus, spina bifida, other malformations of the nervous system, (eye, ear, face, 
and neck) group, cardiac, circulatory system, respiratory system, cleft palate & cleft 
lip, digestive system, genital organs, urinary system, limbs, other musculoskeletal, 
integument, chromosomal, congenital hydrocele, and other and unspecified congenital 
malformations (details in table 6). 
 
Table 6. Congenital Malformations Codes 
Congenital Malformation ICD-9 Code 
Any malformation 740-759, 778.6 
Anencephalus 740 
Spina bifida 741 
Other malformations of the nervous 
system 
742 
Eye, ear, face and neck 743, 744 
Cardiac malformations  745.0-746.9 
Circulatory system 747 
Respiratory system 748 
Cleft palate and cleft lip 749 
Digestive system 750-751 
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Genital organs 752 
Urinary system 753 
Limbs 754.4, 754.5, 754.6, 754.7, 755 
Other musculoskeletal malformations 
754.0, 754.1, 754.2, 754.3, 754.8, 754.9, 
756 
Integument 757 
Chromosomal  758 
Congenital hydrocele 778.6 
Other and Unspecified Congenital 
Anomalies  
759  
 
4.4 Maternal exposure to beta2-agonists 
The primary exposure was the use of SABA (salbutamol, epinephrine, 
orciprenaline, terbutaline, fenoterol, and pirbuterol) and LABA (salmeterol and 
formoterol) during the first trimester of pregnancy, measured separately by the filling 
of at least one prescription during the 1st trimester or just before it, with the likelihood 
of its use during the 1st trimester. The secondary exposure studied was defined as the 
average number of doses per week of SABA taken during the first trimester, obtained 
with an algorithm that we developed and used in previous studies. [11;55;61] The 
average number of doses per week were divided into four categories based upon the 
Canadian Asthma Consensus Guidelines: non-use (0 dose, reference category), > 0 to 
3 doses, > 3 to 10 doses, and > 10 doses per week.[150] 
 
4.5 Confounding variables  
The covariables that we considered were identified from previous studies in the 
literature on asthma during pregnancy, or being known risk factors for congenital 
malformations, hence they were adjusted for as potential confounders. Three classes of 
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variables were considered as potential confounders. Three classes of variables were 
chosen from the literature on asthma during pregnancy or were known risk factors for 
congenital malformations, hence they were considered as potential confounders. 
Maternal socio-demographic variables such as maternal age at the start of pregnancy 
(<18, 18-34, and >34 years), receipt of social assistance during pregnancy or one year 
before (yes/no), area of residence at delivery (rural/urban), and education level in years 
(<12, >13, missing). Maternal & fetal conditions include maternal hypertension 
(chronic and pregnancy induced), diabetes (mellitus and gestational) and epilepsy that 
were identified from either diagnoses or filled prescriptions of related medications one 
year before or during pregnancy using algorithms developed for each 
condition.[11;135;138;143;144] We also considered other maternal diseases such as 
uterine defects, placental embolism, and amniotic bands, measured each separately 
(yes/no) using ICD-9 codes (see table 7). [148;151;152] This class also includes 
maternal exposure to proven human teratogenic drugs during the first trimester of 
pregnancy (yes/no), listed in Table 8. Fetal conditions include embryonic and fetal 
infections (yes/no), identified using ICD-9 codes (see table 7).[148;151;152] 
Pregnancy related variables in this class are parity (nullipara versus primipara or 
multipara) and multiple pregnancies (singleton versus twins or more). Asthma-related 
variables include the use of ICS in the first trimester categorized into (0 mcg, >0-500 
mcg, >500 mcg of beclomethasone chlorofluorocarbon (CFC) equivalent doses per 
day) [135], use of other asthma controller medications (leukotriene-receptor 
antagonists, theophyllines, ipratropium, cromoglycate, and nedocromil) in the first 
trimester of pregnancy (yes/no), and intra-nasal corticosteroids (INCS) use during the 
first trimester (yes/no). Severity and control of asthma prior to pregnancy were 
measured with validated indexes developed according to the Canadian Asthma 
Consensus Guidelines, where severity is classified into mild, moderate or severe and 
control into controlled or uncontrolled.[139]  During the first trimester of pregnancy, 
asthma severity and control were measured using the administered daily doses of ICS, 
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the use of other asthma medications (INCS and asthma controller medications), 
emergency department (ED) visit for asthma, hospital admission for asthma, and the 
use of oral corticosteroids. 
 
Table 7. Maternal and Fetal Conditions 
Embryonic and Fetal Infections ICD-9 Code 
Cytomegalovirus Infection 771.1 
Rubella 771.0 
Herpes Simplex 771.2 
Syphilis 
090.0, 090.1, 090.2, 090.3, 090.4, .5, .6, 
.7, .9 
Toxoplasmosis 771.2 
Varicella-Zoster 052.0, .1, .7, .8, .9 
Venezuelan Equine Encephalitis 66.2 
Maternal Disease States ICD-9 Code 
Uterine complications during pregnancy  
Uterine defects 218.0, 218.1, 218.2, 218 .9, 654.1. 
Placental embolism 656.9 
Amniotic bands 658.8, 762.8 
Rheumatic cases 710.0, 710.2 
Maternal Epilepsy 345, 780.39 
Maternal Diabetes (gestational and 
diabetes mellitus) 
Algorithm based upon filled 
prescriptions of medications and 
diagnosis 
Maternal Hypertension (pregnancy 
induced and chronic hypertension) 
Algorithm based upon filled 
prescriptions of medications and 
diagnosis 
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Table 8. Proven Teratogenic Drugs [153-156]  
acarbose diethylstilboestrol 
acetylsalicylic acid doxepine 
administered hydrochloride doxorubicin  
amethopterine enalapril 
amitriptyline  epirubicin  
amoxapine estramustine  
amsacrine ethopropazine                   
benazepril  ethosuximide    
benztropine  ethylestrenol 
biperidene  etoposide 
bleomycin etretinate 
bupropion  fludarabine  
busereline  fluorouracil 
busulfan fluoxymesterone 
butorphanol  flupenthixol  
capecitabine fluphenazine  
captopril fluspirilene 
carbamazepine fluvoxamine  
carboplatine formestane 
carmustine fosinopril 
chlorambucil gliclazide 
chlorpromazine  glimepiride 
chlorpropamide glyburide 
cilazapril haloperidol 
cilazapril/hydrochlorothiazide hydroxy-urea 
cisplatine imipramine  
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citalopram  interferon alfa - 2A 
cladribine 
interferon alfa - 2A (without human 
albumin) 
clobazam interferon alfa - 2B 
clomipramine  
interferon alfa - 2B (without human 
albumin) 
clozapine interferon alfacon-1 
cyclophosphamide interferon alfa-n1 
cytarabine isotretinoine 
dacarbazine lamotrigine 
dactinomycin l-asparaginase 
danazol levetiracetam 
daunorubicine      lisinopril 
desipramine  lisinopril/hydrochlorothiazide 
lithium pipotiazine  
lomustine primidone 
loxapine  procarbazine  
maprotiline prochlorperazine 
mechlorethamine  procyclidine 
melphalan promazine  
mephenytoine propylthiouracil 
mephobarbital protriptyline 
mercaptopurine quetiapine 
mesoridazine  quinapril  
mesuximide ramipril 
metformin repaglinide 
methimazole risperidone 
methotrimeprazine rosiglitazone 
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methyltestosterone sertraline  
mirtazapine sodium divalproex  
misoprostol sodium valproate 
mitomycin stanozolol 
mitotane temozolomide 
mitoxantrone  testosterone  
moclobemide thioguanine 
nandrolone thioproperazine 
nateglinide thioridazine  
nefazodone thiotepa 
nortriptyline  thiothixene 
olanzapine tolbutamide 
orphenadrine topiramate 
oxcarbazepine trandolapril 
oxymetholone tranylcypromine  
paroxetine  trifluoperazine 
penicillamine trihexyphenidyl 
pericyazine trimipramine 
perindopril  valproic acid 
perindopril/indapamide venlafaxine  
perphenazine vigabatrin 
phenelzine vinblastine  
phenobarbitone vincristine  
phensuximide vindesine  
phenytoine warfarin 
pimozide zuclopenthixol  
pioglitazone   
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4.6 Statistical analyses 
We calculated descriptive statistics for the characteristics of the pregnancies and we 
estimated the prevalence of all, major, and specific congenital malformations according to 
the use of SABA and LABA during the 1st trimester. We also calculated descriptive 
statistics for the characteristics of the pregnancies in relation to the secondary exposure, 
namely the four categories on the average number of doses per week of SABA used during 
the 1st trimester. 
Generalized estimating equation (GEE) models were used to estimate the 
association between the risk of congenital malformation and maternal exposure to SABA 
and LABA during the 1st trimester of pregnancy. Two GEE models were used, one for the 
outcome “major malformations”, the other for the outcome “all malformations”. For both, 
we estimated the crude and adjusted odds ratio (cOR, aOR) of congenital malformations, 
and unstructured correlation matrix was chosen for the analysis. Another two GEE models 
were used to estimate the association between the number of weekly doses of SABA and 
the primary outcomes. GEE models were used as they can take into account the fact that a 
proportion of women contributed two pregnancies or more to the analysis by estimating the 
correlation between consecutive pregnancies and estimate the effects of all 
confounders.[157] A backward selection strategy was used to find the most accurate models, 
retaining in the final models only variables that act as confounders (i.e. if the OR 
associated with SABA or LABA changed by 10% or more) and those significantly 
associated with the outcome (P value < .05).[158] Additional GEE models were performed 
to explore the association between the maternal exposure to SABAs and LABAs during the 
first trimester and specific malformations. For these models, a forward selection strategy 
was used to obtain the best models through adding the variables one by one in descending 
order of significance, then keeping only the variables that act as confounders.[159-161] A 
forward selection strategy was preferred for these models due to the relative small sample 
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sizes and in order to include the least number of variables to maintain the models’ stability. 
All analyses were performed using SAS version 9.1.2.[162] 
 
4.7 Sample Size and Statistical Power 
We planned to have 13307 pregnancies from asthmatic women in the cohort. We expected 
that 55% of women used SABA and 1.3% used LABA during the first trimester. 
Assuming an alpha error of 5%, and considering the prevalence for any malformations to 
be 9.5%, we assumed to have a power of 95% to detect an odds ratio of 1.2 for the SABA 
users against non users, and 83% power to detect an odds ratio of 1.6, or 70% power to 
detect an odds ratio of 1.5 for LABA users against non users. 
For major malformations, we expected a prevalence of 5.9%. Assuming an alpha error of 
5%, the study would have a power of 80% to detect an odds ratio of 1.2, (or 97% to detect 
an odds ratio of 1.3) comparing SABA users and non users. The study would also have a 
power of 82% to detect an odds ratio of 1.8 for LABA users against non users. 
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At a glance commentary: the study helps clinical practitioners to assess the safety of beta2-
agonists during pregnancy in order to optimize their therapeutic strategies in the 
management of asthma. Health practitioners should encourage their pregnant patients to 
adhere to their beta2-agonists therapy; in the meanwhile, long-acting beta2-agonists should 
be the objective of future research. 
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Abstract 
Background: Short-acting inhaled beta2-agonists (SABA) are frequently used as rescue 
medications and long-acting inhaled beta2-agonists (LABA) are used as an add-on 
controller therapy for asthma during pregnancy. Objective: To investigate the association 
between exposure to SABA and LABA in the first trimester of pregnancy and the risk of 
congenital malformations among asthmatic women. Methods: A cohort of pregnancies 
from asthmatic women was formed through linkage of three administrative databases from 
Québec (Canada). The primary outcomes were major and any congenital malformations. 
The primary exposure was the separate exposure to SABA and LABA during the first 
trimester while secondary exposure was the weekly SABA doses during the first trimester. 
Using generalized estimating equation models, the association between congenital 
malformations and maternal exposure to SABA and LABA was assessed. Moreover, the 
association between different specific congenital malformations and maternal exposure to 
SABA and LABA was also examined. Results: From a cohort of 13, 117 pregnancies, we 
identified 1,242 infants with a congenital malformation (9.5%), of which 762 had a major 
malformation (5.8%). The adjusted odds ratios (95% CI) for any malformations associated 
with the use of SABA and LABA were 1.0 (0.9-1.2) and 1.3 (0.9-2.1), respectively. The 
corresponding figures were 0.9 (0.8-1.1) and 1.3 (0.8-2.4) for major malformations. 
Significant increased risks of cardiac, genital organs and other congenital malformations 
were observed with LABA use in 1st trimester. Conclusion: Our study supports the 
evidence that the use of SABA during pregnancy is safe, but more research is required to 
validate the safety of LABA. 
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Introduction 
Asthma has been recognized as one of the most common chronic pulmonary diseases and a 
serious medical complication in pregnancy, [1-3] affecting about 3.7% to 8.4% of pregnant 
women.[1;2] Uncontrolled maternal asthma has been associated with intrauterine growth 
restriction (IUGR), prematurity, and congenital malformations that may lead to 
compromised fetal growth,[1;4-7] with two main hypothesized mechanisms: 1) oxygen 
deprivation due to poor asthma control; and 2) asthma medications.[8] According to the 
US National Asthma Education and Prevention Program guidelines for managing asthma 
during pregnancy, short-acting beta2-agonists (SABAs) are the drug of choice as a quick 
relief medication and in the management of acute exacerbations or emergency 
hospitalizations, while long-acting beta2-agonists (LABAs) are used in combination with 
inhaled corticosteroids as a controller medication for patients with a moderate to severe 
persistent asthma that is not fully controlled with inhaled corticosteroids alone.[9] 
 
Despite their recommended use in asthma management,[9] the beta2-agonists contribution 
to congenital malformations is still unclear. Congenital malformations are present in 
approximately 4% of live births and are considered as the leading cause of infant mortality 
in the US and Canada.[10;11] 
 
In the literature, we identified 15 different studies examining the association between 
SABA and LABA and congenital malformations,[12-26] but only seven studies compared 
beta2-agonists users against a reference group of asthmatic pregnant women[14;16-
18;21;23;26]. Among these studies, only one had uncovered a positive association between 
fenoterol exposure any time during a pregnancy (SABA) and the risk of congenital 
malformation (pOR=1.6, 95% CI=1.3-2.0),[23] but the OR was not adjusted for the level 
of asthma severity. The main limitations that prevent us from drawing valuable and explicit 
conclusions about the safety of SABA and LABA in pregnancy from these 15 studies are: 
1) the choice of the control group, often made up of non-asthmatic women; 2) the timing of 
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the exposure during pregnancy; 3) low statistical power; and 4) incomplete adjustment for 
asthma severity/control and other important confounders.  
 
In order to further investigate the impact of beta2-agonists use during pregnancy, we 
performed a large population-based retrospective cohort study estimating the risk of 
congenital malformations among newborns of mothers who have been exposed to SABA 
and/or LABA during the first trimester of pregnancy. 
 
 
Methods  
Source of Data  
A cohort of pregnancies from asthmatic women was formed through the linkage of three 
administrative health databases from the province of Quebec; Régie de l’assurance maladie 
du Québec (RAMQ), MED-ECHO, and the “Fichier des événements démographiques du 
Québec” (birth and death registries) administered by the Institut de la Statistique du 
Québec (ISQ).  
 
Study Design 
To achieve our goal, a population-based retrospective cohort design was used. The cohort 
has been used before to answer other research questions and details can be found in Blais 
et al.[27]. Briefly, a cohort comprising pregnant asthmatic women insured by the RAMQ 
Public Drug Insurance Plan who gave birth between January 1, 1990 and December 31, 
2002 was formed. The inclusion criteria were: 1) having at least one pregnancy ending in a 
delivery (live or still birth) between 1990 and 2002; 2) being 12-50 years old at the 
beginning of the pregnancy; 3) having at least one diagnosis of asthma (ICD-9 code 493 
except 493.2) and at least one prescription for an asthma medication at any point of time in 
the prior two years or during pregnancy; and 4) being covered by the RAMQ Public Drug 
Insurance Plan for at least one year before and throughout the pregnancy. Pregnancies of 
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women taking oral beta2-agonists during the first trimester and those taking oral 
corticosteroids chronically in the year before conception were excluded, due to the 
previously proven increased risk of congenital malformations among women exposed to 
oral corticosteroids during pregnancy.[28-30] We also excluded pregnancies of women 
who were rheumatic cases, or suffering from Cushing disease, iodine deficiency, adrenal 
tumors, and folic acid deficiency, which are all rare diseases that can affect fetal 
development.[31] 
 
Using the gestational age and date of birth of the newborns recorded in the MED-ECHO 
and ISQ databases, we identified the date of the first day of the last menstrual period and 
the date of delivery for each pregnancy. Pregnancy variables recorded in the RAMQ, 
MED-ECHO and ISQ databases have been found to be highly valid among asthmatic 
women.[32] A woman in the cohort may have contributed more than one pregnancy, the 
“pregnancy” is thus taken as the unit of analysis, with a maximum number of three 
pregnancies per woman, specifically the most recent pregnancies. This research project has 
been approved by the Ethics Committee of the Hôpital du Sacré-Cœur de Montreal.  
 
Congenital Malformations 
The presence of a congenital malformation was identified within the cohort using 
International Classification of Diseases-9th revision (ICD-9) diagnosis codes specific to 
congenital malformations recorded in the RAMQ or MED-ECHO databases at birth or 
during the first year of life. The primary outcomes were major and any congenital 
malformations while the secondary outcomes were specific congenital malformations.  
 
Maternal Exposure to Beta2-agonists 
The primary exposure was the use of SABA (salbutamol, epinephrine, orciprenaline, 
terbutaline, fenoterol, and pirbuterol) and LABA (salmeterol and formoterol) during the 
first trimester of pregnancy, measured separately by the filling of at least one prescription 
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during the 1st trimester or just before it, with the likelihood of its use during the 1st 
trimester. The secondary exposure studied was defined as the average number of doses per 
week of SABA taken during the first trimester, obtained with an algorithm that we 
developed and used in previous studies. [7;27;33;34] The average number of doses per week 
were divided into four categories based upon the Canadian Asthma Consensus 
Guidelines[35]: non-use (0 dose, reference category), > 0 to 3 doses, > 3 to 10 doses, and > 
10 doses per week. 
 
Potential Confounders 
Three classes of variables were chosen from the literature on asthma during pregnancy or 
were known risk factors for congenital malformations, hence they were considered as 
potential confounders: 1) maternal socio-demographic variables include age in years, 
receipt of social assistance during pregnancy or one year before, area of residence at 
delivery, and education level at delivery in years; 2) maternal and fetal conditions 
include chronic hypertension, pregnancy induced hypertension, diabetes mellitus, 
gestational diabetes, epilepsy, uterine complications during pregnancy, maternal exposure 
to teratogenic drugs in the 1st trimester, parity, multiple pregnancies, and embryonic and 
fetal infections; and 3) asthma-related variables include the use of inhaled 
corticosteroids, use of other controller medications (i.e. Leukotriene receptor-antagonist 
[zafirlukast and montelukast], Ipratropium, Theophylline, or anti-allergics [nedocromil and 
cromoglycate]), use of intranasal and oral corticosteroids, and emergency department (ED) 
visit or hospitalization for asthma in the 1st trimester. In addition, asthma severity and 
asthma control were measured with validated index in the year prior to the pregnancy.[36]  
 
Statistical Analysis 
We calculated descriptive statistics for the characteristics of the pregnancies and we 
estimated the prevalence of all, major, and specific congenital malformations according to 
the use of SABA and LABA during the 1st trimester. Generalized estimating equation 
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(GEE) models were then used to estimate the association between the risk of congenital 
malformation and maternal exposure to SABA and LABA during the 1st trimester of 
pregnancy. 
 
 
Results 
The cohort was formed of 13,117 pregnancies. Among these pregnancies, 7,182 (54.8%) 
used SABA during the first trimester of pregnancy while 165 (1.3%) used LABA. 
Regarding the SABA users, 3,420 (26.1%) pregnancies used < 3 doses per week, 2102 
(16.0%) >3 to 10 doses per week whereas 1,660 (12.7%) used >10 doses per week.  
The characteristics of the pregnancies as a function of SABA and LABA use are presented 
in Table I. Most of the women were between 18 and 34 years old, received social 
assistance, had 11 years or less of education, were living in urban areas, and were not 
nulliparas. Less than 3% had a uterine complication or a fetal infection during pregnancy, 
used a teratogenic drug in the 1st trimester, or had a multiple pregnancy. LABA users were 
more likely to suffer from diabetes (gestational and chronic), epilepsy, or fetal infections 
compared to non users. In addition, LABA users were more likely to have exacerbations 
for asthma requiring an ED visit or hospitalization for asthma, to use higher doses of 
inhaled corticosteroids (e.g. ICS>500), intranasal corticosteroids, oral corticosteroids, and 
other asthma controller medications in the 1st trimester, as well as being more likely to 
have severe and uncontrolled asthma in the year prior to pregnancy than non users. 
Regarding the characteristics of the pregnancies in relation to the number of doses of 
SABA taken per week in the 1st trimester (see Table E.1), women taking >10 doses per 
week were more likely to use a teratogenic drug in the 1st trimester as well as higher doses 
of inhaled and oral corticosteroids. They were also more likely to visit an ED or being 
hospitalized for asthma in the 1st trimester and to suffer from severe and uncontrolled 
asthma during the year before pregnancy.  
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As presented in Table II, we identified 1,613 congenital malformations in 1,242 infants 
(prevalence; 9.5%) and 955 major malformations in 762 infants (prevalence; 5.8%). 
Cardiac and musculoskeletal malformations were the most prevalent (16.3% each), 
followed by limb malformations (9.7%). 
In Table III, we present the adjusted odds ratios of any and major malformations associated 
with SABA and LABA use. We found that SABA use in the 1st trimester was not 
associated with an increased risk of any (aOR, 1.0; 95% CI, 0.9-1.2) and major 
malformations (aOR, 0.9; 95% CI, 0.8-1.1). However, LABA users were found to be more 
likely to have a congenital malformation, but the ORs were not statistically significant 
(aOR, 1.3 for any and major malformations). From the GEE models, we also observed that 
pregnancy induced hypertension, diabetes mellitus, and multiple pregnancy were 
significantly associated with an increased risk of any malformations, while pregnancy 
induced hypertension, maternal epilepsy, and multiple pregnancy were significantly 
associated with an increased risk of major malformations. 
Table IV presents the analysis of the doses of SABA taken per week, which revealed no 
association with any or major malformations.  
 
In Table V, we present the association between specific malformations and SABA and 
LABA use in the 1st trimester. We observed no significant association between SABA use 
and any of the specific malformations. On the other hand, significant increased risks of 
cardiac malformations (aOR, 2.4; 95% CI, 1.1-5.1), genital organ malformations (aOR, 
6.8; 95% CI, 2.6-18.1), and other congenital malformations (aOR, 3.4; 95% CI, 1.4-8.5) 
were observed with LABA use in the 1st trimester. 
 
 
Discussion 
In this study, we found no increased risk of congenital malformations with SABA exposure 
during the 1st trimester even among women taking >10 doses per week. We also found no 
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statistically significant increased risk of any and major congenital malformations with the 
use of LABA in the 1st trimester, but this exposure was significantly associated with a 
higher risk of certain malformations; namely cardiac, genital organs, and other and 
unspecified congenital malformations. 
This study is the first to uncover a statistically significant association between maternal 
exposure to LABA in the 1st trimester and congenital malformations. The previous studies 
found no association with any congenital malformations.[12;13;20;21;23;26;37-39] In a 
study which investigated the adverse maternal and fetal risks due to salmeterol 
exposure[26], salmeterol users were compared to women using only SABA and non 
asthmatics. No statistically significant differences were observed in the prevalence of 
major congenital malformations between the three groups, but the study had only a power 
of 9.1% to detect an OR of 1.5. In a retrospective cohort study using the Swedish Birth 
Registry[12], no association between salmeterol and formoterol exposure during the 1st 
trimester and congenital malformations were found. Moreover, in a case-control study 
using the same registry[13], a non significant increased risk of cardiovascular defects was 
found with salmeterol maternal exposure in early pregnancy (aOR, 1.5; 95% CI, 0.90-
2.53), but the non-exposed group was formed by a mix of asthmatic women not using 
salmeterol and non-asthmatic women, and the study had only a statistical power of 34% to 
detect the observed OR. A recent matched case-control study by Tata et al.[21]with The 
Health Improvement Network database in the UK found no association between LABA use 
anytime during pregnancy (aOR, 1.12; 95% CI, 0.72-1.75) and in the 1st trimester (aOR, 
1.09; 95% CI, 0.62-1.90) with major malformations, but the statistical power of the study 
to detect an OR of 1.5 was only 48%.  
 
Among the seven studies that investigated SABA use during pregnancy and congenital 
malformations[12-14;20-23], only three studies used a control group of asthmatic women, 
[14;21;23] with only one of them reporting a significant increased risk of congenital 
malformation [23]. Tamasi et al found a positive association between fenoterol exposure 
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and all malformations (pOR, 1.6 95% CI, 1.30-2.0), [23] but this OR was not adjusted for 
asthma severity, maternal diseases, and medication use.  
Our study results are consistent with the other two studies which used asthmatic pregnant 
women as the control group. Schatz et al. in a large prospective cohort study[14] found no 
increased risk of major malformations among women exposed to SABA anytime during 
pregnancy (cOR, 0.65) or in the 1st trimester (cOR 0.73). In a recent matched case-control 
study, Tata et al. [21] also found no significant increased risk of congenital malformations 
with SABA use anytime during pregnancy (aOR, 1.06; 95% CI, 0.94-1.19) and during the 
1st trimester (aOR, 1.01; 95% CI, 0.86-1.18). 
 
Three studies using non-asthmatic women or the general population as the control group 
found a positive association between SABA and congenital malformations. Kallen et 
al.[12] found a positive association between terbutaline and all malformations (aOR, 1.11; 
95% CI, 1.04-1.19), and between salbutamol and any cardiac defect (aOR, 1.38; 95% CI, 
1.12-1.70), but these ORs were not adjusted for important covariables such as asthma 
severity use of teratogenic medications, multiple pregnancies, and maternal and fetal 
diseases. In a case-control study, Shao Lin et al.[20] reported an increased risk of 
gastroschisis, a major para-umbilical wall defect, with maternal use of salbutamol and 
pirbuterol in the 1st trimester of pregnancy (cOR, 1.62), but the ORs were neither adjusted 
for asthma severity nor asthma control. Shao Lin et al. in another matched case-control 
study[22] reported an increased risk of congenital heart defects with maternal use of 
salbutamol in the 1st trimester (aOR, 2.37; 95% CI, 0.90-6.23). However, the study 
suffered from limitations such as inadequate control for asthma severity and the possibility 
of selection bias since the response rate was below 60% and recall bias as the study 
subjects were contacted up to two years after the birth of the child. 
 
The most important question that should be considered when interpreting our results is 
what are the possible explanations behind the association found between LABA use and 
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specific congenital malformations? We suggest three explanations that could have 
contributed to the observed associations. First, the possibility of residual confounding by 
severity – LABA users appear to have more severe and uncontrolled asthma – and LABA 
are indicated in cases of moderate to severe asthma[3;40] while exacerbations (a marker of 
severe asthma) have been shown to significantly increase the risk of malformations[7]. 
However, we tried to reduce residual confounding through our adjustment for several 
markers of asthma severity and control in the analyses.[41;42] It is also worth noting that 
despite the fact that women using high doses of SABA per week (>10) appeared, like 
LABA users, to have more severe and uncontrolled asthma and were less likely to have a 
baby with a major malformation (aOR, 0.70; 95% CI, 0.50-1.00) than women not using 
SABA. This result implies that confounding by severity is not likely to be present, or not 
strong enough to confound the association to the point that SABA use would be associated 
with an increased risk of congenital malformations.  
 
The second explanation is a true causal association between LABA use during the 1st 
trimester and an increased risk of certain congenital malformations by unknown 
mechanisms that need to be explored on the molecular basis in animal and human studies. 
The third explanation is an increased risk of congenital malformations resulting from the 
potential effect of LABA on the steroid function.  
 
Two different interactions of LABA on steroids have been identified, through which 
LABA could induce the gene transcription effect of steroids and subsequently their effects. 
First, LABA induce protein kinase A (PKA) activation which, in return, induces CAMP 
response element binding protein (CREB) binding protein (CBP). CBP activation is 
considered a rate limiting transcription factor for the steroids’ action.[43] Second, LABA 
can directly induce ligand-independent nuclear translocation and activation of 
glucocorticoid receptors (GR) (i.e. induce migration of GR into the nucleus).[43;44] The 
theory postulates that by inducing the steroid-induced gene transactivation, LABA might 
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also enhance the steroid-induced side effects[43] and among the proven side effects of oral 
corticosteroids is the risk of congenital malformations.[28-30]  
 
This study has several strengths, namely the use of three rich databases which allowed for 
adequate statistical power for the SABA analysis (80% power to detect an aOR of 1.2 for 
any and major malformations) and for adjustment for the most important potential 
confounders, while having a control group of asthmatic women not exposed to SABA or 
LABA during the 1st trimester. Furthermore, data on filled prescriptions and medical 
services were prospectively collected, avoiding a recall bias.  
 
The SABA doses-per-week analysis that we performed helped to explore if there was a 
dose-response relationship between SABA and the risk of congenital malformations. 
Moreover, our large cohort of pregnancies allowed us to investigate congenital 
malformations in three aspects; 1) major malformations; 2) any malformations; and 3) 
specific malformations. The observed significant associations between pregnancy induced 
hypertension, diabetes mellitus, and multiple pregnancy with an increased risk of any 
malformations, also pregnancy induced hypertension, maternal epilepsy, and multiple 
pregnancy with an increased risk of major malformations are in concordance with the data 
in the literature, which emphasize the validity of our final models.[17;27;31;33] Regarding 
the external validity of our study, the prevalence of major and any congenital 
malformations among our cohort was similar to the average population figures.[45]  
 
However, the results of this study should be interpreted with the following limitations in 
mind. The use of medications was measured by medication claims, which might not reflect 
their actual intake. The medications dispensed in hospitals were not recorded in the RAMQ 
database, which may include oral corticosteroids, and this could have underestimated their 
use during pregnancy. The cases of congenital malformations were identified using 
diagnoses recorded in the RAMQ and MED-ECHO databases and were not specifically 
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validated for this study. There is also a possibility of residual confounding due to our 
incapacity to adjust for known risk factors, like maternal obesity, over the counter 
medications (OTC), alcohol consumption, family history of congenital malformations, and 
some other environmental teratogens.[31] We only had a statistical power of 30% and 20% 
to detect a 30% increased risk of any malformations and major malformations, 
respectively, among LABA users. Moreover, in our study we did not adjust the P-values 
for multiple comparisons in the analyses of specific malformations, but the association of 
LABA exposure with genital organs malformations and other and unspecified 
malformations had very small P-values (P=0.0001, and P=0.008 respectively). Finally, the 
cohort under represents women with a higher socioeconomic status, which may limit the 
study generalizability, but this would be unlikely since the association between beta2-
agonists and congenital malformations is believed to be physiological in nature.  
 
In conclusion, our study adds evidence, in concordance with asthma management 
guidelines, to the safety of SABA use during pregnancy even at doses as high as ten per 
week, but puts doubts on the use of LABA during pregnancy since they were found to be 
associated with an increased risk of certain congenital malformations. However, the 
observed associations cannot be entirely attributed to LABA since there is a possibility of 
residual confounding by asthma severity and further research is required to understand the 
aetiology behind these relationships. We also propose the substantial need to examine the 
results we reported in this study using in-vivo and in-vitro techniques.  Due to the proven 
risks of severe and uncontrolled asthma on the mother and her fetus, risk-benefit 
considerations should still favour LABA use in asthma management during pregnancy 
until further results are reported. 
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Table I. Characteristics of Pregnancies According to SABA and LABA Use during the First Trimester  
  SABA Users 
SABA Non 
Users LABA Users 
LABA Non 
Users 
  No. of Pregnancies (%) 
 7,182 (54.8) 5,935 (45.2) 165 (1.3) 12,952 (98.7) 
Socio-demographic variables     
Maternal age (years)     
<18 535 (7.4) 320 (5.4) 7 (4.2) 848 (6.6) 
18-34 6,182 (86.1) 5,261 (88.6) 134 (81.2) 11,309 (87.3) 
>35 465 (6.5) 354 (6.0) 24 (14.6) 795 (6.1) 
Receipt of social assistance during 
pregnancy or one year before 5,873 (81.8) 4,537 (76.4) 102 (61.8) 10,308 (79.6) 
Urban area of residence at delivery 5,796 (80.7) 4,816 (81.2) 130 (78.8) 10,482 (80.9) 
Level of education at delivery (years)     
<11 4,313 (60.1) 3,465 (58.4) 76 (46.1) 7,702 (59.5) 
12-15 2,026 (28.2) 1,665 (28.1) 64 (38.8) 3,627 (28.0) 
>16 323 (4.5) 347 (5.8) 14 (8.5) 656 (5.1) 
missing 520 (7.2) 458 (7.7) 11 (6.7) 967 (7.5) 
Maternal & fetal conditions     
Chronic hypertension 183 (2.6) 131 (2.2) 9 (5.5) 305 (2.4) 
Pregnancy induced hypertension 323 (4.5) 265 (4.5) 8 (4.9) 580 (4.5) 
Diabetes mellitus 181 (2.5) 123 (2.1) 12 (7.3) 292 (2.3) 
Gestational diabetes 574 (8.0) 441 (7.4) 28 (17.0) 987 (7.6) 
Epilepsy 80 (1.1) 59 (1.0) 4 (2.4) 135 (1.0) 
Use of teratogenic drugs in 1st trimester 112 (1.6) 57 (1.0) 5 (3.0) 164 (1.3) 
Uterine complications during pregnancy 140 (2.0) 113 (1.9) 4 (2.4) 249 (1.9) 
Fetal infections during pregnancy 56 (0.8) 33 (0.6) 4 (2.4) 85 (0.7) 
Nullipara 2,546 (35.7) 1,616 (27.3) 67 (40.6) 4,095 (31.8) 
Multiple pregnancy 100 (1.4) 90 (1.5) 2 (1.2) 188 (1.5) 
Asthma related variables     
Daily dose of inhaled corticosteroids in 
1st  trimester* (μg)     
0 3,178 (44.3) 5,459 (92.0) 8 (4.9) 8,629 (66.6) 
>0-500 3,489 (48.6) 446 (7.5) 80 (48.5) 3,855 (29.8) 
>500 515 (7.2) 30 (0.5) 77 (46.7) 468 (3.6) 
Use of other controller medications in 
1st trimester† 360 (5.0) 36 (0.6) 22 (13.3) 374 (2.9) 
Use of intranasal corticosteroids in 1st 
trimester 375 (5.2) 144 (2.4) 25 (15.2) 494 (3.8) 
Use of oral corticosteroids in 1st 
trimester 408 (5.7) 44 (0.7) 31 (18.8) 421 (3.3) 
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Emergency department visit or 
hospitalization for asthma in 1st 
trimester 
579 (8.1) 76 (1.3) 22 (13.3) 633 (4.9) 
Exacerbations for asthma in 1st 
trimester‡ 717 (10.0) 98 (1.7) 31 (18.8) 784 (6.1) 
Asthma severity in the year before 
pregnancy     
Mild 5,011 (69.8) 5,760 (97.1) 48 (29.1) 10,723 (82.8) 
Moderate  1,447 (20.2) 163 (2.7) 47 (28.5) 1,563 (12.1) 
Severe 724 (10.1) 12 (0.2) 70 (42.4) 666 (5.1) 
Asthma control in the year before 
pregnancy     
Controlled 3,093 (43.1) 4,900 (82.6) 35 (21.2) 7,958 (61.4) 
Un-controlled 4,089 (56.9) 1,035 (17.4) 130 (78.8) 4,994 (38.6) 
 
SABA: short-acting inhaled β2-agonist, LABA: long-acting inhaled β2-agonist,  
*ICSs in beclomethasone dipropionate-chloroflurocarbon equivalent. 
†Leukotriene receptor-antagonist (zafirlukast and montelukast), Ipratropium, Theophylline, or Anti-allergics (nedocromil 
and cromoglycate).  
‡A filled prescription for oral corticosteroids, an emergency department visit for asthma, or a hospitalization for asthma. 
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Table II. Distribution of Congenital Malformations   
Congenital Malformation All Malformations Major Malformations 
  No. % No. % 
At least one malformation* 1,242 9.5 762 5.8 
Specific malformations     
Anencephalus 2 0.1 2 0.2 
Spina bifida 10 0.6 10 1.1 
Other malformations of the nervous system 94 5.8 94 9.9 
Eye, ear, face and neck 106 6.6 63 6.6 
Cardiac malformations 262 16.3 262 27.5 
Circulatory system 103 6.4 71 7.4 
Respiratory system 56 3.5 38 4.0 
Cleft palate and cleft lip 31 1.9 31 3.3 
Digestive system 134 8.3 121 12.7 
Genital organs 101 6.3 22 2.3 
Urinary system 62 3.9 62 6.5 
Limbs 156 9.7 22 2.3 
Other musculoskeletal malformations 263 16.3 79 8.3 
Integument 41 2.5 25 2.6 
Chromosomal 20 1.2 20 2.1 
Congenital Hydrocele 45 2.8 2 0.2 
Other congenital anomalies 125 7.8 29 3.0 
Total† 1613 100 955 100 
 
*At least one malformation from total number of pregnancies (13,117). 
†The number and percentage represents the total number of malformations in all cases. The total exceeds the number 
of cases (1,242 for all malformations and 762 for major malformations), because a newborn may have had more than 
one malformation. 
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Table III. Crude and Adjusted Odds Ratios of Any and Major Malformations in Association with SABA and 
LABA Use during the First Trimester of Pregnancy 
 
SABA: short-acting inhaled β2-agonist, LABA: long-acting inhaled β2-agonist, N/R: not retained 
 
 
 
 
 
 Any Malformations Major Malformations 
 No. of 
pregn-
ancies 
No. of 
Cases (%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95%CI) 
No. of 
Cases 
(%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95%CI) 
 
SABA use in 1st trimester  
Yes 7,182 691 (9.6) 1.0 (0.9-1.2) 1.0 (0.9-1.2) 410 (5.7) 1.0 (0.8-1.1) 0.9 (0.8-1.1) 
No 5,935 551 (9.3) reference reference 352 (5.9) reference reference 
LABA use in 1st  trimester  
Yes 165 21 (12.7) 1.4 (0.9-2.2) 1.3 (0.9-2.1) 13 (7.9) 1.4 (0.8-2.4) 1.3 (0.8-2.4) 
No 12,952 1,221 (9.4) reference reference 749 (5.8) reference reference 
Receipt of social assistance 
during pregnancy or 1 year 
before 
 
Yes 10,410 999 (9.6) reference N/R 626 (6.0) reference reference 
No 2,707 243 (9.0) 0.9 (0.8-1.1) N/R 136 (5.0) 0.8 (0.7-1.0) 1.2 (1.0-1.5) 
Pregnancy induced 
hypertension   
Yes 588 73 (12.4) 1.4 (1.1-1.8) 1.4 (1.1-1.7) 48 (8.2) 1.5 (1.1-2.0) 1.5 (1.1-2.0) 
No 12,529 1,169 (9.3) reference reference 714 (5.7) reference reference 
Diabetes mellitus  
Yes 304 42 (13.8) 1.5 (1.1-2.1) 1.5 (1.1-2.1) 25 (8.2) 1.5 (1.0-2.2) 1.4 (0.9-2.1) 
No 12,813 1,200 (9.4) reference reference 737 (5.8) reference reference 
Epilepsy  
Yes 139 20 (14.4) 1.6 (1.0-2.6) N/R 16 (11.5) 2.1 (1.3-3.6) 2.1 (1.2-3.5) 
No 12,978 1,222 (9.4) reference N/R 746 (5.8) reference reference 
Multiple pregnancy  
Yes 190 43 (22.6) 2.9 (2.0-4.1) 2.9 (2.0-4.0) 29 (15.3) 3.0 (2.0-4.5) 3.0 (2.0-4.5) 
No 12,927 1,199 (9.3) reference reference 733 (5.7) reference reference 
Use of intranasal 
corticosteroids in 1st  
trimester 
 
Yes 519 54 (10.4) 1.1 (0.8-1.5) N/R 39 (7.5) 1.3 (0.9-1.9) 1.4 (1.0-1.9) 
No 12,598 1,188 (9.43) reference N/R 723 (5.7) reference reference 
Emergency department visit 
or hospitalization for asthma 
in 1st  trimester 
 
Yes 655 72 (11.0) 1.2 (0.9-1.5) N/R 47 (7.2) 1.3 (0.9-1.7) 1.3 (0.9-1.7) 
No 12,462 1,170 (9.4) reference N/R 715 (5.7) reference reference 
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Table IV. Adjusted Odds Ratios of Any and Major Malformations in Association with the Number 
of Doses of SABA Taken per Week and LABA Use during the First Trimester of Pregnancy 
 
SABA: short-acting inhaled β2-agonist, LABA: long-acting inhaled β2-agonist, N/R: not retained 
* OR adjusted for pregnancy induced hypertension, diabetes mellitus, and multiple pregnancy. 
†OR adjusted for pregnancy induced hypertension, diabetes mellitus, epilepsy, use of teratogenic drugs in 1st  trimester, 
multiple pregnancy, use of intranasal corticosteroids in 1st trimester, emergency department visit or hospitalization for 
asthma in 1st trimester, and asthma severity in the year before pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Any Malformations* Major Malformations† 
 No. of 
Pregnancies
No. of Cases 
(%) 
Adjusted OR 
(95% CI) 
No. of Cases 
(%) 
Adjusted OR 
(95% CI) 
 
SABAs doses per week in 
1st trimester 
 
0 5935 551 (9.3) reference 352 (5.9) reference 
>0-3 3420 342 (10.0) 1.1 (0.9-1.3) 209 (6.1) 1.0 (0.8-1.2) 
>3-10 2102 208 (9.9) 1.1 (0.9-1.3) 115 (5.5) 0.8 (0.7-1.1) 
>10 1660 141 (8.5) 0.9 (0.7-1.1) 86 (5.2) 0.7 (0.5-1.0) 
LABA use in 1st trimester  
Yes 165 21 (12.7) 1.4 (0.9-2.2) 13 (7.9) 1.2 (0.7-2.2) 
No 12952 1221 (9.4) reference 749 (5.8) reference 
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Table V. Adjusted OR and 95% CI of Different Specific Malformations in Association with 
SABA and LABA Use during the First Trimester of Pregnancy 
Congenital 
Malformation SABA LABA 
 Users n (%) 
Non users
n (%) OR (95 % CI) 
Users 
n (%) 
Non users
n (%) OR (95 % CI)
Anencephalus* 1 (0.0) 1 (0.0) 0.8 (0.1-13.2) 0 (0.0) 2 (0.0) N/A 
Spina bifida† 7 (0.1) 3 (0.1) 1.4 (0.3-6.5) 0 (0.0) 10 (0.1) N/A 
Other malformations of 
the nervous system‡ 60 (0.8) 34 (0.6) 1.4 (0.9-2.2) 3 (1.8) 91 (0.7) 2.3 (0.7-7.7) 
Eye, ear, face and neck§ 59 (0.8) 47 (0.8) 1.2 (0.8-1.8) 2 (1.2) 104 (0.8) 1.2 (0.3-5.0) 
Cardiac malformations¶ 132 (1.8) 130 (2.2) 0.8 (0.6-1.1) 7 (4.2) 255 (2.0) 2.4 (1.1-5.1) 
Circulatory system** 60 (0.8) 43 (0.7) 1.0 (0.6-1.6) 4 (2.4) 99 (0.8) 2.7 (0.9-8.0) 
Respiratory system†† 32 (0.5) 24 (0.4) 1.0 (0.5-1.8) 1 (0.6) 55 (0.4) 0.7 (0.1-4.9) 
Cleft palate and cleft 
lip* 20 (0.3) 11 (0.2) 1.5 (0.7-3.1) 0 (0.0) 31 (0.2) N/A 
Digestive system‡ 75 (1.0) 59 (1.0) 1.1 (0.8-1.5) 0 (0.0) 134 (1.0) N/A 
Genital organs‡‡ 58 (0.8) 43 (0.7) 1.3 (0.8-1.9) 5 (3.0) 96 (0.7) 6.8 (2.6-18.1)
Urinary system§§ 36 (0.5) 26 (0.4) 1.2 (0.7-2.1) 1 (0.6) 61 (0.5) 0.9 (0.1-6.0) 
Limbs¶¶ 89 (1.2) 67 (1.1) 1.3 (0.9-1.8) 1 (0.6) 155 (1.2) 0.6 (0.1-4.5) 
Other musculoskeletal 
malformations‡ 149 (2.1) 114 (1.9) 1.1 (0.9-1.4) 3 (1.8) 260 (2.0) 0.9 (0.3-2.8) 
Integument*** 25 (0.4) 16 (0.3) 1.0 (0.5-1.8) 0 (0.0) 41 (0.3) N/A 
Chromosomal††† 11 (0.2) 9 (0.2) 0.6 (0.3-1.3) 1 (0.6) 19 (0.2) 1.8 (0.3-12.9)
Congenital 
Hydrocele‡‡‡ 28 (0.4) 17 (0.3) 1.1 (0.6-2.1) 1 (0.6) 44 (0.3) 1.4 (0.2-10.4)
Other congenital 
malformations§§§ 79 (1.1) 46 (0.8) 1.4 (1.0-2.1) 5 (3.0) 120 (0.9) 3.4 (1.4-8.5) 
 
N/A: not applicable 
Forward selection strategy used for adjusted OR models 
* OR adjusted for all confounding variables (no variables retained in the final model) 
† OR adjusted for asthma control in the year before pregnancy 
‡ OR adjusted for all confounding variables 
§ OR adjusted for daily dose of inhaled corticosteroids in 1st trimester 
¶ OR adjusted for multiple pregnancy 
** OR adjusted for daily dose of inhaled corticosteroids in 1st trimester 
†† OR adjusted for daily dose of inhaled corticosteroids in 1st trimester 
‡‡ OR adjusted for daily dose of inhaled corticosteroids in 1st trimester and multiple pregnancy 
§§OR adjusted for daily dose of inhaled corticosteroids in 1st trimester and asthma severity in the year before pregnancy 
¶¶ OR adjusted for asthma control in the year before pregnancy and asthma severity in the year before pregnancy 
*** OR adjusted for asthma severity in the year before pregnancy 
††† OR adjusted for daily dose of inhaled corticosteroids in 1st trimester and asthma severity in the year before pregnancy 
‡‡‡ OR adjusted for asthma control in the year before pregnancy 
§§§ OR adjusted for multiple pregnancy and use of oral corticosteroids in 1st trimester 
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Table E 1. Characteristics of Pregnancies According to the Number of Doses of SABA Taken per Week 
during the First Trimester 
Number of doses of SABA per week 
  0 >0-3 >3-10 >10 
  No. of pregnancies (%) 
 5,935 (45.2) 3,420 (26.1) 2,102 (16.0) 1,660 (12.7) 
Socio-demographic variables     
Maternal age (years)     
<18 320 (5.4) 275 (8.0) 176 (8.4) 84 (5.0) 
18-34 5,261 (88.6) 2,948 (86.2) 1,787 (85.0) 1,447 (87.2) 
>35 354 (6.0) 197 (5.8) 139 (6.6) 129 (7.8) 
Receipt of social assistance during 
pregnancy or one year before 4,537 (76.4) 2,820 (82.5) 1,718 (81.7) 1,335 (80.4) 
Urban area of residence at delivery 4,816 (81.2) 2,781 (81.3) 1,703 (81.0) 1,312 (79.0) 
Level of education at delivery (years)     
<11 3,465 (58.4) 2,102 (61.5) 1,283 (61.0) 928 (55.9) 
12-15 1,665 (28.0) 915 (26.7) 581 (27.6) 530 (31.9) 
>16 347 (5.9) 149 (4.4) 96 (4.6) 78 (4.7) 
missing 458 (7.7) 254 (7.4) 142 (6.8) 124 (7.5) 
Maternal & fetal conditions     
Chronic hypertension 131 (2.2) 82 (2.4) 53 (2.5) 48 (2.9) 
Pregnancy induced hypertension 265 (4.5) 144 (4.2) 113 (5.4) 66 (4.0) 
Diabetes mellitus 123 (2.1) 89 (2.6) 53 (2.5) 39 (2.4) 
Gestational diabetes 441 (7.4) 272 (8.0) 169 (8.0) 133 (8.0) 
Epilepsy 59 (1.0) 35 (1.0) 19 (0.9) 26 (1.6) 
Use of teratogenic drugs in 1st 
trimester 57 (1.0) 49 (1.4) 26 (1.2) 37 (2.2) 
Uterine complications during 
pregnancy  113 (1.9) 71 (2.1) 40 (1.9) 29 (1.8) 
Fetal infections during pregnancy  33 (0.6) 25 (0.7) 19 (0.9) 12 (0.7) 
Nullipara 1,616 (27.3) 1,163 (34.2) 766 (36.7) 617 (37.4) 
Multiple pregnancy 90 (1.5) 40 (1.2) 29 (1.4) 31 (1.9) 
Asthma related variables     
Daily dose of inhaled corticosteroids 
in 1st trimester* (μg)     
0 5,459 (92.0) 1,855 (54.2) 903 (43.0) 420 (25.3) 
>0-500 446 (7.5) 1,517 (44.4) 1,097 (52.2) 875 (52.7) 
>500 30 (0.5) 48 (1.4) 102 (4.9) 365 (22.0) 
Use of other controller medications in 
1st trimester† 36 (0.6) 79 (2.3) 79 (3.8) 202 (12.2) 
Use of intranasal corticosteroids in 1st 
trimester 144 (2.4) 128 (3.7) 117 (5.6) 130 (7.8) 
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Use of oral corticosteroids in 1st 
trimester 44 (0.7) 79 (2.3) 108 (5.1) 221 (13.3) 
Emergency department visit or 
hospitalization for asthma in 1st 
trimester 
76 (1.3) 152 (4.4) 189 (9.0) 238 (14.3) 
Exacerbations for asthma in 1st 
trimester‡ 98 (1.7) 178 (5.2) 235 (11.2) 304 (18.3) 
Asthma severity in the year before 
pregnancy     
Mild 5,760 (97.1) 3,142 (91.9) 1,537 (73.1) 332 (20.0) 
Moderate  163 (2.8) 251 (7.3) 426 (20.3) 770 (46.4) 
Severe 12 (0.2) 27 (0.8) 139 (6.6) 558 (33.6) 
Asthma control in the year before 
pregnancy     
Controlled 4,900 (82.6) 2,184 (63.9) 785 (37.4) 124 (7.5) 
Un-controlled 1,035 (17.4) 1,236 (36.1) 1,317 (62.7) 1,536 (92.5) 
 
SABA: short-acting inhaled β2-agonist, LABA: long-acting inhaled β2-agonist.  
*ICSs in beclomethasone dipropionate-chloroflurocarbon equivalent. 
†Leukotriene receptor-antagonist (zafirlukast and montelukast), Ipratropium, Theophylline, or Anti-allergics (nedocromil 
and cromoglycate).  
‡A filled prescription for oral corticosteroids, an emergency department visit for asthma, or a hospitalization for asthma. 
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Discussion 
6.1 General discussion 
Asthma is recognized as one of the most common chronic pulmonary diseases and 
a serious medical complication in pregnancy. [1-3] Most studies suggest that more severe 
asthma during pregnancy is associated with increased fetal and maternal risks, while 
better-controlled asthma is associated with decreased risks. [1;4] Treatment and control of 
asthma could be achieved by many drugs, but none of them has been classified as 
completely safe for use during pregnancy. SABA have been widely used for years to 
control asthma symptoms during pregnancy, which is not the case for LABA. More data on 
the safety of SABA, especially Salbutamol, are available due to greater pregnancy 
experience.[3] 
 
 Among the studies that examined the association between SABA and LABA 
exposure during pregnancy and congenital malformations, two studies found a positive 
association between SABA use and congenital malformations.[26;36], while LABA use 
wasn’t found associated with congenital malformations in any study. Moreover, concerns 
about the methodologies and conduct of the previous studies have been raised. Our study 
tried to investigate the association between maternal exposure to SABA and LABA during 
the first trimester of pregnancy and the risk of major, all, and specific congenital 
malformations, while avoiding the weaknesses of other studies in the literature. 
 
In our study, we found no increased risk of congenital malformations with SABA exposure 
during the 1st trimester even among women taking >10 doses per week on average during 
the first trimester. We also found no significant increased risk of any and major congenital 
malformations with the use of LABA in the 1st trimester. On the other hand, significant 
increased risks of cardiac malformations (aOR, 2.4; 95% CI, 1.1-5.1), genital organ 
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malformations (aOR, 6.8; 95% CI, 2.6-18.1), and other congenital malformations (aOR, 
3.4; 95% CI, 1.4-8.5) were observed with LABA use in the 1st trimester.  
 
6.2 Contribution of our results to the literature in the field of asthma and 
pregnancy 
Looking into the literature, SABA use during pregnancy has been found to be 
associated with congenital malformations in only two studies,[26;36] from which only one 
had a control group of unexposed asthmatic women.[36] However, SABA use hasn’t been 
found to be associated with congenital malformations in other studies.[14;27;28;30-32;35] 
All previous studies examining SABA suffered from some methodological limitations 
which could alter their results. Our results came in concordance with studies that 
investigated SABA use during pregnancy and found no association with congenital 
malformations. To our knowledge, none of the previous studies examined SABA 
thoroughly in the form of SABA doses per week analysis. So, analysing SABA use in 
doses per week gave us more certainty about their safety in pregnancy at higher doses. The 
high statistical power of the SABA analyses increases our confidence about the safety of 
these medications.  
 
LABA use during pregnancy is considered safe and recommended in most asthma 
management guidelines.[3;163] Previous studies suggested their safe use during 
pregnancy, and no association has been reported between their use in the management of 
asthma during pregnancy and an increased risk of congenital 
malformations.[26;27;33;35;36;39] These studies provide some evidence on the safety of 
LABA; however a final conclusion on their safety can’t be drawn due to limitations in 
these studies.  
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Although we didn’t find a significant increased risk of major or any malformations with 
LABA use in the 1st trimester, we found a significant association between LABA use in the 
1st trimester and a higher risk of certain malformations; namely cardiac, genital organs, and 
other and unspecified congenital malformations. We suggested three explanations that 
could have contributed to the observed associations; the possibility of residual confounding 
by severity, a true causal association between LABA use during the 1st trimester and an 
increased risk of certain congenital malformations by unknown mechanisms, or an 
increased risk of congenital malformations resulting from the potential effect of LABA on 
the steroid function. 
 
 
6.3 Strengths of the study 
 
6.3.1 Databases 
One of the strengths in our study is the use of prospectively gathered data from 
administrative databases. Using the interlinked three large Quebec’s databases to identify 
the exposures and outcomes provided many advantages over other methods of data 
collection such as self-reported questionnaire or a personal interview. [164-166] 
 
 First, data on filled prescriptions and medical services were prospectively collected, 
avoiding a recall bias. Second, using administrative computerized databases helped to find 
the history of the medication use over long periods (one year before and during 
pregnancy), and for huge number of subjects. Third, it has been reported that patients 
mostly have difficulties in reporting the details of their medication use, such as time, doses, 
and quantity.[167-170] 
 Fourth, using administrative databases, we had the ability to study a large number of 
pregnant women in a reasonable budget and time-frame. Fifth, data recorded in the RAMQ 
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Medication Prescription database and the medical diagnosis for asthma recorded in the 
RAMQ Medical Services database have been formally evaluated and found to be valid and 
precise.[141;142] The RAMQ and MED-ECHO databases have often been used for 
research on asthma and pregnancy with many articles published in renowned medical 
journals.[11;135;138;143;144] Sixth, the use of three rich databases allowed for adequate 
statistical power for the SABA analysis (80% power to detect an aOR of 1.2 for any and 
major malformations) and for adjustment for most important potential confounders, while 
having a control group of asthmatic women not exposed to SABA or LABA during the 1st 
trimester. 
 Pregnancy variables recorded in the RAMQ, MED-ECHO and ISQ databases have 
been formally evaluated and found to be highly valid.[171] From the variables that have 
been validated and were used to perform our analyses are maternal age, length of gestation, 
date of delivery, and date of last menstruation. The validity of the variables was assessed 
by calculating Pearson correlation coefficient between the values obtained from the 
databases and patents’ medical charts, and the correlations were found to be high for all 
variables ranging from 0.920 to 0.999.   
 
6.3.2 Study methodology 
An important principle in studying medication teratogenic safety profile is that an 
exposure to the medication (teratogen) is said to be following a toxicologic dose-response 
curve, where there is a threshold below which no effect will be observed. [88;89;104] Also 
as the dose of the teratogen increase, both severity and frequency of the adverse fetal effect 
increase.[89]The SABA doses-per-week analysis that we performed helped to explore if 
there was a dose-response relationship between SABA and the risk of congenital 
malformations. To our knowledge, this is the first study to investigate SABA in such 
manner. An analysis of medication’s toxicological effects (e.g. teratogenicity) in such way 
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is the ideal choice, in order to reveal if there is a threshold below which no effects are 
observed.[88;89]  
 
Our large cohort of pregnancies (13,117 asthmatic pregnant women) allowed us to 
investigate risk of congenital malformations with SABA and LABA use in three aspects; 
1) major malformations; 2) any malformations; and 3) specific malformations. The 
assessment of specific malformations risk, which is uncommon in previous studies, could 
help investigators in the future to focus on the reported results in this study and try to 
uncover the reasons behind the association. 
 
6.4 Limits of the study 
6.4.1 Error and bias in the study 
Two types of error could alter study results; random error and systematic error 
(bias).[164-166]  
Random error 
Random error (chance effect) is defined as the variability in the data and it 
represent the precision of the estimate. Random error usually diminishes as sample size 
gets larger. A small P-value and a narrow confidence interval are reassuring signs against 
chance effect.[164-166] As mentioned earlier, we had a large cohort of pregnancies 
allowing for adequate statistical power for the SABA analysis (80% power to detect an 
aOR of 1.2 for any and major malformations). However, we only had a statistical power of 
30% and 20% to detect a 30% increased risk of any malformations and major 
malformations, respectively, among LABA users. This may imply that there might be a 
real association between LABA and any and major congenital malformations but we didn’t 
have enough power to detect it. We also had small sample sizes with some specific 
malformations, but with other groups we had larger sample sizes and higher ORs allowing 
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to report highly significant results (cardiac malformations aOR, 2.4; 95% CI, 1.1-5.1, 
genital organ malformations aOR, 6.8; 95% CI, 2.6-18.1, and other congenital 
malformations aOR, 3.4; 95% CI, 1.4-8.5 with LABA use).  
 
Systematic error 
Systematic error (systematic bias) is a result of an error in the method the study was 
conducted. It could result due to errors in the way the subjects were selected, errors in the 
measurement of variables, or any confounding factor that is not completely controlled for. 
Systematic error mainly influences the internal validity of the study. Systematic bias can be 
classified into selection bias, information bias, and confounding bias .[164-166] Selection 
bias (selection effect) refers to any error that arises in the process of identifying the study 
populations, and in a cohort it is usually related to losses to follow-up.[164-166] In our 
study we don’t believe that we faced a situation in which this kind of bias could have 
altered our results. 
 
Information bias 
Information bias occurs as a result of systematic differences in the way data on 
exposure, outcome, or confounders are obtained from the various study groups.[164-166] 
Misclassification is the reason behind information bias, which can be differential or non-
differential misclassification.[164-166] 
 
In retrospective cohort studies, in which information is obtained from past records, 
differential misclassification could be present if the quality and accuracy of information 
obtained is different among exposed and non-exposed persons.[166] In our study, the 
assessment of the outcome (cases of congenital malformations) was identified using 
diagnoses codes recorded in the RAMQ and MED-ECHO databases (administrative 
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databases) and were not specifically validated for this study, but the assessment of the 
outcome was made independently of the exposure status of the mother. Consequently, if 
there was any inaccuracy in outcome measurement, it will not be related to exposure status 
and only non-differential misclassification may have resulted. Non-differential 
misclassification generally dilutes the effect (towards null effect) and produces 
underestimation of the OR, in other words the real associations could be larger than those 
that we observed in our study.[164] Regarding the non-significant results in our study, 
non-differential misclassification might have also played a role (together with the small 
sample size issue) to prevent unveiling an increased risk of malformations in some groups. 
 
Regarding the exposure assessment, the use of medications was measured by 
medication claims, which might not reflect their actual intake; therefore a non-differential 
misclassification of exposure might have been introduced, and that might have led to an 
underestimation of the associations. However, an article showed that only 6% of drugs 
dispensed for pregnant women were not used.[172]  
 
Another limitation in our study concerning the use of the RAMQ database is that it 
doesn’t record medications dispensed in hospitals, which may include oral corticosteroids, 
and this could have underestimated their use during pregnancy. Oral corticosteroids, as 
mentioned before, have been associated with an increased risk of congenital 
malformations.[145-147] Since women using high doses of SABA and women using 
LABA usually suffer from moderate or severe asthma, and were more likely to be 
hospitalized and have OCS, a differential misclassification might have been introduced. 
However, we do not believe this could have strongly impacted our findings on the SABA 
and LABA safety as the percentages of hospitalized patients were small. In both cases, in 
the case of differential misclassification, an overestimation of the effect of SABA or 
LABA on congenital malformations might have occurred. 
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Confounding bias 
Confounding is mixing of the effect of the exposure under study on the disease 
(outcome) with that of a third factor that is associated with the exposure ,an independent 
risk factor for the disease, and not in the causal  pathway between exposure and disease 
(even among individuals non-exposed to the exposure factor under study). The 
consequence of confounding is that the estimated association is not the same as the true 
effect and an extraneous risk factor could be the alternative reason behind the association 
(or part of the association) observed between the exposure and the outcome.[164-166] In 
order to reduce the impact of confounding in our study, we used multivariate regression 
models to adjust the ORs for several confounding covariables at the same time (see 
potential confounders and statistical analysis sections in the manuscript). We included the 
majority of  known risk factors of congenital malformations in our  models, however, due 
to our incapacity to adjust for a few known risk factors, like maternal obesity, over the 
counter medications (OTC), alcohol consumption, family history of congenital 
malformations, and some other environmental teratogens,[148] there is a possibility of 
residual confounding in our models.  
 
Another confounding issue in the study is a possible residual confounding by 
severity present in the association between LABA use in the first trimester and the risk of 
congenital malformations. As mentioned earlier, LABA users are likely to have more 
severe and uncontrolled asthma since the percentages of moderate and severe asthma in the 
year before pregnancy among LABA users were 28.5% and 42.4% respectively against 
12.1% and 5.1% among non-users, and the percentage of uncontrolled asthma among 
LABA users was 78.8% against 38.6% among non-users. Also, ED visits or 
hospitalizations for asthma and exacerbations for asthma during the first trimester were 
higher among LABA users against LABA non-users (13.3% and 18.8% against 4.9% and 
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6.1%), and exacerbations have been shown to significantly increase the risk of 
malformations.[11] However, we tried to reduce residual confounding through our 
adjustment for several markers of asthma severity and control in the analyses, as the use of 
OCS, the daily dose of ICS, use of other asthma controller medications and intranasal 
corticosteroids, ED visit or hospitalization for asthma, and exacerbations for asthma in the 
1st trimester, as well as asthma severity and control in the year before pregnancy.[173;174] 
It is also worth noting that despite the fact that women using high doses of SABA per week 
(>10) appeared, like LABA users, to have more severe and uncontrolled asthma (based 
upon our findings, percentage of severe asthmatic patients who used SABA >10 doses per 
week was 33.6% against 0.2% among non-users and percentage of uncontrolled asthma 
was 92.5% against 17.5% among non-users) , women using high doses of SABA per week 
(>10) were less likely to have a baby with a major malformation (aOR, 0.70; 95% CI, 0.50-
1.00) than women not using SABA. This result tends to reveal that confounding by 
severity, if present, is not likely to be strong enough to have meaningfully overestimate the 
association between LABA use and congenital malformations. 
 
Considering the nature of data used and the different types of bias our study 
suffered from, a sensitivity analysis approach might be appealing which is multiple-bias 
modelling. Multiple-bias models constitutes the modification of the Monte-Carlo 
sensitivity analysis (MCSA) procedure in a way that improves the Bayesian interpretability 
of MCSA methods.[175] Multiple-bias models depend on identifying priors for different 
bias distribution parameters and computing the odds ratios adjusted for these biases 
through sequential procedure of expressions.[175;176] The problem of applying multiple-
bias modelling in our study is that the priors on bias parameters could be inaccurate, and 
biases might actually operate in a much more complicated way (correlation between 
biases).Using multiple-bias modelling, it has been shown that the less information about 
biases and the higher the uncertainty about applying results from the literature or 
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assumptions on bias parameters, the more uncertainty emerges in the resulting model-
based estimates.[175;176] 
 
6.4.2 Other limitations 
All studies using repeated statistical analysis simultaneously in one population to 
assess several drug exposures are subject to multiple comparisons problems and inference 
error, resulting in statistically significant P-values by chance alone.[177] As usual in 
studies of drug safety, we used P-value <0.05 as the level for statistical significance, even 
if several comparisons were performed. We didn’t adjust for multiple comparisons in our 
study since the largest numbers of comparisons were made for the analysis of specific 
congenital malformations, which were considered as secondary outcomes. 
 
6.5 External validity 
External validity refers generally to which extent a study’s findings could be 
applied to other non-study populations (generalizability).[164-166;178] Our cohort under 
represents women with a higher socioeconomic status. This is because our database 
included women covered by the public drug insurance of the RAMQ which includes 
women receiving social assistance and middle class working women. However, this under 
representation might limit the study generalizability only if socio-economic status is 
believed to be an effect modifier for the association between the exposure in our study and 
congenital malformations, but this would be unlikely since the association between beta2-
agonists and congenital malformations is believed to be physiological in nature. Moreover, 
one of the reassuring points on the appropriateness of our study findings regarding the 
external validity is that the prevalence of major and any congenital malformations among 
our cohort was similar to the average population figures.[179]  
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6.6 Clinical implications of the results 
The findings in our study can be directly transferred to physicians and specialists 
for management of asthma during pregnancy. Our results could be very useful in adding to 
the physicians’ trust in SABA as a quick relief medication and solves some benefit-risk 
fears. An additional benefit from our results is the assurance in the safe use of SABA 
during the first trimester of pregnancy even at high doses (>10 doses per week). 
 
While our results suggests that the use of LABA during pregnancy might carry a 
significant risk on the fetal health, we still can’t define a clear-cut for that issue until 
further research on these medications are made on larger scale and avoiding the limitations 
we encountered in our study. Therefore, what we can propose is that physicians can 
optimize their strategy of management of asthma during pregnancy and the use of LABA 
through continuous reassessment of the patients’ classification of asthma, trying to 
minimize the medication used to achieve control of asthma through using the step down 
approach in the guidelines in order to avoid unnecessary use of these medications until 
other findings.  
 
6.7 Further research 
In the field of asthma medication use during pregnancy, there are still many 
questions that need to be answered in proper means. We still have numerous questions 
regarding the safety of many asthma medications during pregnancy, and what should be 
the best regimen to control asthma during pregnancy, while reducing the maternal and fetal 
risks due to asthma disease and medications themselves.  
Regarding beta2-agonists use during pregnancy, none of them is considered 
absolutely safe during pregnancy, and they will remain an open field for further research 
until we obtain a complete safety profile for each drug in the group. 
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The findings in our study could have an impact for future research. The associations 
reported between LABA use and specific congenital malformations could encourage 
researchers from pharmaceutical and pharmacology fields to further investigate LABA in 
animal models and on the molecular basis to disentangle any relationship with congenital 
malformations, taking into account the suggested synergistic relationship between LABA 
and corticosteroids, and the previously reported risks of corticosteroids on fetal 
development. 
 
From our part, we could further study the risk associated with LABA use using a 
larger cohort of pregnancies from asthmatic women. A larger cohort could help us obtain 
higher statistical power and adjust for multiple comparisons. Another interesting question 
that could be the objective of further research is the association between maternal exposure 
to SABA and LABA and other maternal and fetal outcomes, such as low birth weight, 
prematurity and small for gestational age baby, and how this could add to the safety profile 
of these medications. There is considerable lack of knowledge on the safety of SABA and 
LABA during pregnancy, and any future work exploring their use during pregnancy would 
be of great value. 
 
 
Conclusion 
Consistent with the literature, our study adds evidence to the safety of SABA use 
during pregnancy, and that comes in concordance with asthma management guidelines. 
Also we didn’t find any dose-response relationship between SABA and congenital 
malformations. These results could be very useful in adding to the physicians’ trust in 
SABA and solves some benefit-risk fears. On the other hand, LABA use during the first 
trimester was associated with cardiac, genital organs, and other congenital malformations. 
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The observed associations found with LABA exposure can’t be attributed entirely to the 
drug effect since there is a possibility of residual confounding by asthma severity. Since 
there is a possibility of residual confounding by asthma severity and further research is 
required to understand the aetiology behind these relationships, due to the proven risks of 
severe and uncontrolled asthma on the mother and her fetus, risk-benefit considerations 
should still favour LABA use in asthma management during pregnancy until further results 
are reported.  
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